In situ forming hydrogels and composition designs for use in utero
Patent Information
- Application Number
- JP2023528567
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-09
- Filing Date
- 2021-11-11
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-11-11
AI Technical Summary
Current methods for preventing uterine cavity adhesions after medical procedures are ineffective and prone to issues such as premature dilution and expulsion of hydrogel barriers, leading to incomplete adhesion prevention and increased risk of infertility.
A biodegradable hydrogel system is designed for transcervical delivery, comprising two precursor solutions that mix in situ to form a stable gel within seconds, with a pH-adjusted accelerator solution ensuring rapid crosslinking and resistance to dilution, delivered via a specialized applicator to fill and distend the uterine cavity.
The hydrogel effectively prevents uterine cavity adhesions by maintaining its position and integrity within the uterus for an appropriate duration, reducing adhesion formation and post-operative bleeding, while being minimally invasive and biocompatible.
Smart Images

Figure 2022103944000001 
Figure 2022103944000002 
Figure 2022103944000003
Abstract
Description
Technical Field
[0001] Aspects of the present invention relate to hydrogels designed to be delivered transcervically into the uterine cavity, such as improved devices of these materials, and hydrogels useful for the placement and delivery of such devices.
Background Art
[0002] The unwanted adhesion of scar tissue after a medical intervention is a common complication called adhesions. The formation of adhesions generally occurs when two injured tissue surfaces are in close proximity to each other. This complication can cause debilitating medical problems, including but not limited to postoperative adverse events and failure of medical interventions, that are painful. Adhesions that occur within the uterine cavity after transcervical procedures are often the cause of infertility. The surgical separation of adhesions, a procedure known as adhesiolysis, can lead to the reformation of secondary adhesions. Current methods for preventing the formation of postoperative adhesions, including but not limited to uterine cavity adhesions, are of limited effectiveness.
Summary of the Invention
Means for Solving the Problems
[0003] Some medical applications, particularly hydrogel systems with improved properties for adhesion prevention, are presented. The resulting hydrogels are biodegradable and form hydrogels within seconds of delivery. The hydrogels are biocompatible and soft, but the hydrogels have an appropriate elastic modulus to stay in place against body forces for a desired period. The hydrogel precursor forms a space-filling hydrogel that resists the dilution effect of the surrounding fluid after delivery. The hydrogel system includes mixing two precursors, an electrolyte and a nucleophile, at a pH that limits premature crosslinking prior to delivery. The mixed precursors are blended with a basic buffer in an accelerator solution at the time of delivery to cause gelation.
[0004] Hydrogel systems are useful for methods and applications to prevent adhesions, including but not limited to uterine cavity adhesions, as presented herein. These techniques may also be used to stop undesirable postoperative bleeding and to mechanically support uterine tissue. The material may be introduced into the surgical site to reduce or prevent contact between damaged tissues or between multiple parts of tissue. A fluid component may be used to facilitate the introduction and formation of the material. For example, a fluid polymer precursor may be introduced laparoscopically or transcervically and, after introduction, activated to form the material on or inside the uterus. Examples of precursors include polymerizable / crosslinkable hydrophilic polymers that form the material, e.g., a hydrogel, in the uterine cavity.
[0005] Some embodiments describe methods for preventing adhesion of damaged tissue surfaces in potential spaces such as the uterine cavity. The methods involve introducing a fluid material into the uterine cavity to fill the cavity and tamponade its opposing cavity walls. Tamponade can be effective in reducing bleeding from damaged tissue after surgical procedures and separating the damaged tissue surface, allowing the uterine cavity walls to heal independently. By filling and expanding the uterine cavity, the in-situ forming material is not removed by uterine muscle contractions until structural integrity is lost. The material may be, for example, a hydrogel and may function as a stent or splint. Some embodiments describe methods for preventing intrauterine adhesions by applying a material crosslinking precursor for forming a hydrogel in the uterus, for example, to coat the surface of damaged tissue, or to tamponade the surface of the uterine cavity, or to prevent the collapse and adhesion of the uterine cavity walls to each other. Some polymer systems involve pre-mixing a hydrogel precursor into one solution and combining the precursor solution with a second solution for activation / enhancement, thereby activating crosslinking during application. Embodiments of the applicator may relate to a design in which the application device includes the use of a soft, flexible, non-traumatic catheter and a low catheter profile to reduce the insertion trajectory remaining after removal. For transcervical access to the uterus, the applicator may include or be associated with a flow limiter that helps maintain the hydrogel precursor in the uterine cavity so that separation of the uterine wall is achieved by completely filling the uterine cavity. In some embodiments, the flow limiter may be adjustable along the catheter length to position the catheter port at a specific location in the uterine cavity.
[0006] In one embodiment, the present invention relates to a crosslinked hydrogel composition comprising a multi-arm polyethylene glycol molecule crosslinked with a multifunctional crosslinking agent by biodegradable crosslinking. The hydrogel may have an in vivo intrauterine degradation time of about 1 to about 21 days. For in vivo use, to provide stability without uncomfortable pressure on the patient, the hydrogel may have a Young's modulus value of 5 kPa to 300 kPa. In some embodiments, the crosslinked molecule incorporated into the hydrogel is a polyamine, such as polylysine, which may be trilysine. In some embodiments, the crosslinked functional group is an N-hydroxysuccinimide ester and a primary amine that react to form an amide bond by nucleophilic substitution.
[0007] In another embodiment, the present invention relates to a hydrogel applicator comprising two reservoirs, the outlet of which is connected to a Y-connector, and a section of a tube connected to a catheter having a size of 9Fr or less, having the outlet port on the side of the catheter body with a non-traumatic tip, which mixes the respective solutions from the reservoirs. One reservoir may hold a blend of hydrogel precursors under conditions for sufficiently slow crosslinking, and the other reservoir may contain an accelerator, such as a basic buffer. The reservoirs may be syringe tubes mounted on holders, and the plungers may be connected to plunger caps to allow for convenient simultaneous deployment of two syringe plungers. A static mixer may provide faster mixing of the combined solutions from the reservoirs. The catheter may be formed from a polymer with a sufficiently low durometer value, thus reducing the likelihood of causing injury to patient tissue.
[0008] In a first particular embodiment, the present invention relates to a medical hydrogel system comprising a precursor blend solution and an accelerator solution. The precursor blend solution may comprise an aqueous solvent, a first precursor having a hydrophilic core and succinimidyl ester functional groups, and a second precursor having a plurality of amine functional groups, wherein the precursor blend solution has an acidic pH. The accelerator solution may comprise a buffer solution having a pH above 8.2 and sufficient buffering capacity, thereby raising the pH of the mixture of the precursor blend solution and the accelerator solution to above pH 8.
[0009] In further specific embodiments, the present invention relates to a hydrogel delivery system suitable for intrauterine delivery, comprising a first solution, a second solution, and an applicator. The applicator may include a catheter configured to be placed transcervically in the uterus and having a cap element on the catheter to allow for the prevention of hydrogel outflow from the cervix; a first reservoir for holding the first solution; a second reservoir for holding the second solution; and a mixer configured to receive the first and second solutions and vigorously mix the first and second solutions to form a blend precursor solution for delivery from the mixer to the catheter, the blend precursor solution having a solid content of 5 wt% to 12 wt%. Generally, the blend precursor solution gels in about 30 seconds or less and, after 12 hours, forms a product hydrogel with an initial Young's modulus of more than 1 kPa, and the product hydrogel persists in the uterine environment for 3 to 29 days.
[0010] In another specific embodiment, the present invention relates to a method for delivering an intrauterine hydrogel, the method comprising combining a first solution and a second solution to form a blended solution, and directing the blended solution into a transcervically positioned catheter to deliver the blended solution into the uterus. Generally, the first solution comprises an aqueous solvent and a first precursor having a hydrophilic core and succinimidyl ester functional groups, and a second precursor having a plurality of amine functional groups, and the second solution generally comprises a buffer solution with a pH greater than 8.2. The blended solution is covalently crosslinked to gel in 30 seconds or less, where the catheter has a cap element that can be used to prevent the blended solution from leaking out, and pressure is applied to the gelled hydrogel to produce expansion filling. [Brief explanation of the drawing]
[0011] [Figure 1] This is a diagram of an intrauterine applicator for transcervical delivery of a cross-linked hydrogel precursor solution. [Figure 2] Figure 1 shows a cross-section of the basic installation tip of the hydrogel applicator. [Figure 3] This is a diagram of a hydrogel applicator used to deliver a medical hydrogel system to the uterus via the cervix, with a cap element used to control catheter placement and the outflow of material from the external cervical os. [Figure 4] This is a diagram illustrating various cap element designs. [Figure 5A] This is a diagram showing the assembled configuration of a catheter and an egress limiter. [Figure 5B] Figure 5A shows the separation configuration of the catheter and the outflow limiter. [Figure 6A] This is a diagram of a catheter assembly equipped with an outflow limiter and connector for use with the hydrogel delivery system described herein. [Figure 6B] Figure 6A shows a magnified cross-section of a portion of the catheter assembly and the outflow limiter. [Figure 6C] Figure 6A is an exploded view of the catheter assembly, outflow limiter, and connector. [Figure 7] This is a diagram of a hydrogel delivery system used to deliver a hydrogel polymer composition to the uterus transcervically. [Figure 8] This is a diagram illustrating a transcervical procedure using a hydrogel delivery system equipped with an outflow limiter to fill the uterus with a hydrogel polymer composition. [Figure 9] This is a diagram illustrating a transcervical procedure using a hydrogel delivery system equipped with a cervical plug and an outflow limiter to fill the uterus with a hydrogel polymer composition. [Figure 10] This is a schematic diagram of a hydrogel delivery system used to deliver hydrogel polymer compositions transdermally into body cavities. [Figure 11] The plots of hydrogel swelling in relation to pot life in minutes are shown for the two premixed formulations. [Figure 12] A set of time-dependent modulus plots is shown for gel samples formed from various hydrogel systems and tested at dilution ratios of 5:1, 25:1, 50:1, and 250:1. [Figure 13] A set of time-dependent modulus plots is shown for gel samples formed from various hydrogel systems and tested at dilution ratios of 5:1, 25:1, 50:1, and 250:1. [Figure 14] A set of time-dependent modulus plots is shown for gel samples formed from various hydrogel systems and tested at dilution ratios of 5:1, 25:1, 50:1, and 250:1. [Figure 15] A set of time-dependent modulus plots is shown for gel samples formed from various hydrogel systems and tested at dilution ratios of 5:1, 25:1, 50:1, and 250:1. [Figure 16]Plots of the modulus loss per unit time as a function of dilution rate are shown for three gel samples formed from a premixed formulation and a fourth gel sample formed from a separated formulation. [Figure 17] Plots of the percent modulus and absolute modulus as a function of time are shown for the premixed formulation and the separated formulation in a medium with a dilution rate of 250:1. [Figure 18] A series of photographs of lesions after hysterectomy, taken after using an applicator to place a hydrogel polymer composition after a uterine ablation procedure. The photographs show the excised uterus, the excised uterus cut open to show the placed hydrogel polymer composition, and the cut-open uterus together with the excised hydrogel implant. [Figure 19] Ultrasound images of the uterine cavity of a single patient before ablation (left image), and after ablation and trans-cervical placement of the hydrogel polymer composition (right image). The arrows indicate the uterine cavity and the location of the in-situ formed hydrogel that fills and tamponades the uterine cavity.
Mode for Carrying Out the Invention
[0012] Hydrogel formulations have been discovered that provide unique properties suitable for medical applications, particularly for intrauterine delivery, but hydrogels may be suitable for other appropriate medical treatments. Delivery into the uterine cavity presents several important challenges. With respect to delivery, the precursor solution needs to flow sufficiently to fill the uterine cavity without flowing past the uterotubal junction and into the fallopian tubes or out through the cervix in its initial gel state, and needs to rapidly solidify as a gel to achieve these opposing objectives. The uterine cavity can exert forces to expel multiple materials through the cervix from the uterine cavity, so the hydrogel needs to have sufficient resilience to be maintained within the uterus against these forces. The hydrogels are biodegradable and persist long enough to prevent adhesions, but need to persist for a length that does not contribute to problems themselves. The challenges are significant, but the hydrogels are designed based on a hydrophilic core, particularly a polyethylene glycol core, one precursor having succinimidyl ester functional groups, and a second precursor having multiple amine functional groups. To resist dilution effects, the hydrogel precursors are mixed prior to delivery and combined with an accelerator solution during delivery to effectively fill the uterine cavity while providing the desired modulus and space-filling properties. An effective applicator has been designed to enable easy delivery of the hydrogel. The resulting system is well-suited for effective medical treatments to reduce the risk of uterine cavity adhesions or similar protected spaces within the patient's body.
[0013] Based on a newly designed hydrogel system, an effective method is presented for reducing or eliminating uterine cavity adhesions resulting from medical procedures by delivering a well-designed hydrogel precursor using a suitable applicator. An effective hydrogel precursor can be designed for one or more of the following desirable characteristics: gelation time, viscosity of the precursor solution, degree of swelling after crosslinking, biodegradation time, mechanical properties, or other suitable features. Improvements to these parameters can overcome the shortcomings of previous attempts to deliver hydrogel-based adhesion prevention products. Improved applicators are designed for more effective delivery into cavities such as the uterine space. Improved applicators may include an egress limiter that can suppress the outflow of the hydrogel and / or hydrogel precursor from the cervix before the precursor is fully gelled. A favorable design allows for control of the flow limiter in favorable procedures. The improved applicator is described below, and additional features are described in the concurrently pending U.S. Patent Application No. 17 / 494,752 to Bassett, et al., "Transcervical Access Systems for Intrauterine Fluid Exchange, Such as Hydrogels Formed In Situ" (as incorporated herein).
[0014] In some embodiments, the process of mixing a mixture, or hydrophilic reactive precursor species, involves having nucleophilic functional groups having hydrophilic reactive precursor species and electrophilic functional groups so that they form a crosslinking mixture. If the mixture reacts relatively slowly under neutral conditions, the precursors may be mixed and placed in a syringe or similar reservoir of the delivery system shortly before administration. The accelerator may be placed in another syringe or similar fluid reservoir. The accelerator is mixed with the precursor blend during delivery and may initiate more rapid crosslinking thanks to a change in the pH of the blend or other favorable properties. Since the precursors can be thoroughly mixed before administration, the mixing process may be more complete in the delivery system, and the well-mixed composition is delivered into the catheter for intrauterine delivery.
[0015] Some embodiments of the present invention relate to methods and apparatus for delivering two solutions to form a hydrogel implant in situ. As described herein, a two-component hydrogel system provides an effective use for depositing such a hydrogel system into the uterine cavity, although the hydrogel may be effective in other confined spaces within the patient's body. The method involves preparing a precursor in a suitable applicator equipped with a catheter for receiving the mixed components of the hydrogel system. The catheter may interface with a flow limiter for delivering the hydrogel precursor into a confined space such as the uterine cavity. The flow limiter may be left in place while the catheter is being removed, and the flow limiter or multiple portions thereof may be removed a short time thereafter, with the precursor having sufficiently gelled. In terms of technical terms, a hydrogel system refers to two solutions used to form a hydrogel in a suitable container. The transformation from hydrogel precursor to hydrogel is not a clear conversion. Therefore, the term "hydrogel precursor" can be appropriately used to describe the separated components before the initiation of crosslinking, which leads to gelation by sufficient gelation that the material no longer flows naturally, and "hydrogel" can refer to the material after significant crosslinking, which undergoes a rheological change to a fully solidified hydrogel after sufficient crosslinking. Thus, there is a transient state that can be reasonably described using either term.
[0016] The use of hydrogels for intrauterine use is described in U.S. Patent Application Publication No. 2005 / 0266086 to Sawhney (hereinafter referred to as Application '086) ("Intrauterine Applications of Materials Formed In Situ"). A product commonly marketed for preventing adhesions was known as SprayGel®. Application '086 specifically describes the use of SprayGel® in its examples. The SprayGel® product is also covered in U.S. Patent No. 7,009,034 to Pathak, et al. (hereinafter referred to as Patent '034) ("Biocompatible Crosslinked Polymers"), which is incorporated herein by reference.
[0017] The hydrogel system described herein overcomes the identified shortcomings of previous products. In particular, the improved hydrogel system has good flow that covers the target space without uncontrolled movement of the hydrogel precursor beyond the target region. Furthermore, the hydrogel system is far less susceptible to the effects of dilution. While these improvements are particularly desirable for intrauterine delivery, such as adhesion prevention, hydrogels are also useful for other medical applications, such as adhesion prevention in the abdominal cavity.
[0018] Adhesion (uterine cavity adhesion) Adhesions can form as part of the natural healing process and can connect adjacent injured tissues by distinct fibrous bands. While the adhesion barriers described herein may be applicable to avoid any postoperative adhesion formation, this description focuses on uterine adhesions, for which the compositions are particularly well suited. Other notable adhesion prevention applications include the delivery of hydrogels for adhesion prevention in the abdominal cavity.
[0019] Intrauterine adhesions (IUAs) appear as adhesive bands with distinct or irregular edges, causing distortion of the natural physiological function of the uterus and eventually obstructing the uterine cavity (1). Partial or complete obstruction of the uterine cavity due to adhesions can result in abnormal bleeding, infertility, and recurrent miscarriage (2). For any of these reasons, avoiding intrauterine adhesions is desirable. IUAs are commonly found in patients after gynecological procedures requiring the placement of instruments in the uterus for either diagnostic or therapeutic purposes, or in patients who have suffered trauma within the uterine cavity (3). The incidence of intrauterine adhesion formation after such events can reach 60% (4). Adhesions are a result of surgical hysteroscopy, and their incidence varies depending on the type of procedure involved, and is particularly high in hysteroplasty, myomectomy, and endometrial ablation (5, 6). These conditions, while treating the primary cause of low fertility, increase the risk of adhesions, which represent a more latent risk to fertility. The association between the presence of adhesions and infertility has been reported to reach 43% (3). Furthermore, evidence suggests that the severity of adhesions can progress from mild, thin-membrane adhesions to fibromuscular adhesions and eventually to dense connective tissue (8). Various factors have been associated with the formation of intrauterine adhesions (6, 9, 10, 11, 12).
[0020] Over the past few years, the use of reabsorbable barriers to prevent IUA has shown some clinical success. These barriers include hyaluronic acid solutions, cross-linked hyaluronic acid solutions, and viscoelastic solutions containing hydrophilic polymers. Solutions of hyaluronic acid and cross-linked compounds, such as Sepracoat (a hyaluronic acid-based product, Genzyme), have been shown to be prophylactically effective, but remain ineffective or lack sufficient data to support a reduction in IUA when applied after tissue damage has occurred (17). Viscoelastic forms have shown promising clinical results in the overall reduction of IUA, but remain subject to the effects of premature dilution and require extension of the overall duration. To date, no single modality has proven satisfactorily effective in preventing postoperative adhesion formation in hysteroscopic use (18).
[0021] In-situ-forming hydrogels offer several advantages for use as adhesion barriers. The liquid nature of the precursor allows for ease of use, minimal invasiveness, and thorough application throughout the uterine cavity. After crosslinking and gel formation, the barrier is more resistant to discharge from the uterine cavity and premature dilution. Hydrogel formulations are generally described as being able to achieve durations designed to prevent intrauterine adhesions (IUA). Previous efforts for the application of hydrogels to prevent uterine adhesions are described in the '086 application cited above. An example of application '086' uses a material called SPRAYGEL, which was developed and demonstrated to be useful for preventing intraperitoneal adhesion formation (5, 6, 7) (see Mettler et al., "Prospective Clinical Trial of SprayGel as a Barrier to Adhesion Formation: An Interim Analysis," Journal of the American Association of Gynecological Laparoscopists, (August 2003) 10(3), 339-344, incorporated herein by reference). SPRAYGEL consists of two liquids (one clear and one blue), each containing chemically different polymer precursors, which, when mixed, rapidly crosslink to form a biocompatible, absorbable hydrogel in situ. As described above, additional details regarding hydrogels under SPRAYGEL are provided in patent '034. The evaluation of hydrogel materials for preventing uterine adhesions was carried out using compositions and instruments designed for intraperitoneal application (19, 20). The intrauterine environment presents unique challenges compared to the intraperitoneal environment due to its confined space, uterine muscle contractions, exit pathways from the body, different healing mechanisms after injury, potential dilution due to the presence of fluid in the cavity, and other differences. Therefore, specific compositions are desirable to achieve the target results for preventing uterine adhesions.An improved delivery device for intrauterine application is described in the concurrently pending U.S. Patent Application No. 17 / 494,792 (hereinafter referred to as Application '792) of Bassett, et al. ("Transcervical Access Systems For Intrauterine Fluid Exchange, Such as Placement of Hydrogels Formed In Situ") (as incorporated herein).
[0022] Hydrogels for medical applications Hydrogels are generally considered to be materials that absorb water, swell without recognizable dissolution, and maintain a reversibly deformable three-dimensional network structure. See, for example, Park, et al., Biodegradable Hydrogels for Drug Delivery, Technomic Pub. Co., Lancaster, PA (1993) (incorporated herein). Network structures crosslinked by covalent bonds of hydrophilic polymers, including water-soluble polymers, are traditionally represented as hydrogels (or aquagels) in a hydrated state. Hydrogels have been prepared based on crosslinked polymer chains of methoxypoly(ethylene glycol) monomethacrylate with variable-length polyoxyethylene side chains, and their interactions with blood components have been studied (Nagaoka et al., Polymers as Biomaterial (Shalaby et al., Eds.), Plenum Press, 1983, p.381).
[0023] The crosslinking solutions for use include those that can be used to form implants in lumens or cavities and can form physical crosslinks, chemical crosslinks, or both. Physical crosslinking can occur by complex formation, hydrogen bonding, desolvation, van der Waals interactions, ionic bonding, etc., and can be initiated by mixing two components that are physically separated until they are linked in situ, or as a result of dominant conditions in a physiological environment, such as temperature, pH, ionic strength, etc. Chemical crosslinking can be achieved by any of several mechanisms, including free radical polymerization, condensation polymerization, anionic or cationic polymerization, stepwise polymerization, etc. When two solutions are used, each solution contains components of a co-initiation system that initiate crosslinking immediately upon mixing. These solutions are stored separately and mixed for delivery into tissue lumens. The improved hydrogel systems described herein are based on two solutions that are mixed to chemically crosslink.
[0024] Hydrogels can be spontaneously crosslinked from at least one precursor without the need for a separate energy source. In the case of a two-component system, the mixing of the two solutions is carried out so that the solutions remain fluid while passing through the instrument. If necessary, one or both of the crosslinkable precursor solutions may contain a contrast agent or other means for visualizing the hydrogel implant. The crosslinkable solution may contain a bioactive drug or other therapeutic compound, which is trapped in the resulting implant, so that the hydrogel implant performs a drug delivery function.
[0025] Properties of hydrogel systems other than crosslinking can be selected according to the intended application. For example, when hydrogel implants are used to temporarily block the reproductive organs, such as the uterine cavity, for tamponade, the hydrogel system may swell to some extent to conform to irregular geometric shapes and be biodegradable within the time frame of a single menstrual cycle. The hydrogel is preferably soft, and its modulus or rigidity is lower than that of uterine tissue in a non-pregnant uterus. Other applications may suggest different properties of the hydrogel system. More generally for medical applications, the material should be selected based on its indicated biocompatibility and non-toxicity.
[0026] Since the hydrogel can be biodegradable, it does not need to be recovered from the body. Biodegradability as used herein refers to the predictable disintegration of a material into molecules or particles small enough to be metabolized or excreted under normal physiological conditions. Biodegradation can occur, for example, by hydrolysis, enzymatic action, cell-mediated disruption, or a combination thereof.
[0027] Hydrogel systems formed by chemical cross-linking The hydrogel systems described herein, for providing desired space-filling medical functions, particularly for reducing adhesions, are generally supplied in two solutions that are combined during delivery to the patient's body. Hydrogel precursors may be designed to crosslink spontaneously in a mixed solution based on a nucleophilic-electrophilic reaction. By appropriate design of the hydrogel system, the precursors may be designed so that they are aggregated into one solution that is stable against crosslinking, and the second solution contains an initiator that initiates the crosslinking reaction after mixing.
[0028] Therefore, the first aspect of polymer system design is the formation of a properly stable initial blend of precursors. The polymer precursors should be properly stable so that crosslinking is not significant before delivery, while the blend solution needs to undergo rapid crosslinking. Due to these combinations of features, the form of the solution for delivery may result in a hydrogel with slightly different properties from the hydrogel formed in the solution with different initial forms. The biodegradation rate is influenced by the incorporation of biodegradable bonds into the hydrogel. The basic chemical structures of the hydrogels and their precursors are then described in terms of their general properties, and the properties of the hydrogels are described in more detail below.
[0029] The precursor generally comprises at least two different polymerizable compounds. To form a highly crosslinked hydrogel, both precursors generally each have three or more reactive functional groups for crosslinking. In some embodiments, at least one of the precursor compounds is generally of medium molecular weight and can be a polymer. A water-soluble, polymerizable monomer having a functionality > 1 (i.e., forming a crosslinked network structure immediately upon polymerization) and forming a hydrogel may be referred to herein as a macromer. The second precursor compound may be a compound of medium molecular weight or a small molecule crosslinker. The molecular weight range is further described below. The functional groups of the precursors provide the crosslinking reaction, biodegradability characteristics, and the overall properties of the precursor solution and the product hydrogel.
[0030] When two solutions are used, each solution typically contains one component of the polymerization system that crosslinks upon contact. The solutions are stored in separate compartments of the delivery system and mixed once deposited either on or within the tissue. In contrast, here the polymer system is sufficiently stable, and the two monomers are mixed within the delivery system before delivery and combined with the initiating solution at delivery, where at least one of the monomers is usually a macromer. Generally, pH is used to gate the crosslinking reaction. Therefore, the initiating solution can lower the pH, generally allowing the crosslinking reaction to proceed rapidly.
[0031] When the crosslinking reaction proceeds simultaneously with the mixing of precursors, the morphology of the crosslinked hydrogel may be slightly different. Furthermore, the fluidity of the initial crosslinking solution may also be slightly different, without changing the gelation time. Therefore, when mixing and crosslinking occur simultaneously, the homogeneity of the initial crosslinked product is inferior to that of a mixed precursor solution mixed with an initializing solution that primarily shifts the pH. Increased homogeneity improves the flow of the precursor solution, leading to a gelation time where sufficient crosslinking effectively restricts any further flow. After the gelation time has elapsed, further crosslinking occurs over an additional period.
[0032] In the hydrogel system, functional groups suitable for crosslinking macromers for forming tissue implants in situ may also be conveniently used, including macromers containing groups that are active to functional groups such as amines that may be present in the crosslinking compound. Therefore, multicomponent hydrogel systems can crosslink spontaneously when the components are activated by the initiator system, but two or more components are appropriately stable for an appropriate processing time before activation. Such a system contains, for example, a monomer (macromer or small molecule) that is a difunctional or polyfunctional amine in one component, and a macromer having a difunctional or polyfunctional N-succinimidyl-containing moiety in the other component. The succinimidyl functional group promotes the formation of amide bonds during the reaction with the amine. Components of other initiator systems, such as redox initiators, may also be used. Mixing of two or more solutions may result in condensation polymerization, which may further lead to the formation of implants.
[0033] It has been found that the solid concentration of the hydrogel precursor solution is important for intrauterine delivery. The intrauterine space may contain various bodily fluids, and after medical procedures, blood and residual fluids from the procedure may also be present. While some fluid can be removed before instillation of the hydrogel into the intrauterine space, the hydrogel precursor may be diluted by fluids in the space as the precursor is delivered. This dilution effect was a problem with the original SprayGel® product, which was primarily designed to prevent intraperitoneal adhesions. When diluted in the uterine cavity, the SprayGel® hydrogel may not necessarily fill the cavity, and the modulus of the solidified hydrogel may be lower than the target value. The improved hydrogel described herein is designed to be dilution-resistant.
[0034] The properties of the hydrogel and precursor solution are described in detail below. Important properties include: gelation time, no applicator clogging, no excessive migration, low dilution effect / good spread through the lumen, appropriate biodegradation time, and maintenance of sufficient modulus for the desired period. Due to muscular function, the uterus tends to remove material from the lumen, so modulus below a certain value tends to be easily expelled from the uterine cavity. Parameters that affect these issues include: chemical properties of functional groups, monomer crosslinking density / molecular weight, monomer composition, percentage of solids in the hydrogel precursor, and the chemical properties and ionic strength of buffers.
[0035] Autohydrolysis of the product hydrogel is observed when a premixed precursor containing an acidic amine group is used. Autohydrolysis can lead to the degradation of the hydrogel without affecting biological activity. Autohydrolysis can occur in the initially formed hydrogel before the buffer is completely removed from the hydrogel by osmosis and exchange with body fluids. Autohydrolysis can lead to a premature decrease in the modulus of the hydrogel.
[0036] monomer Crosslinkable monomers may be used to form biocompatible implants. As described above, monomers may be macromers or small molecule crosslinkers, and in either case, may or may not be polymers. The term polymer as used herein means a molecule formed of at least three repeating units. The term reactive precursor species means a crosslinking molecule, e.g., a polymer, functional polymer, macromolecule, small molecule, or small molecule crosslinker that can participate in a reaction to form a hydrogel network structure.
[0037] Monomers may include biodegradable, water-soluble macromers as described in U.S. Patent No. 7,332,566 (hereinafter referred to as "Patent No. 566") to Pathak, et al. ("Biocompatible Crosslinked Polymers With Visualization Agents") (incorporated herein). These monomers are characterized by having at least two polymerizable groups separated by at least one degradable region. When polymerized in water, they form coherent gels, which persist until they are eliminated by biodegradation. Generally, macromers are formed having a core of water-soluble and biocompatible polymers, such as polyalkylene oxides, which may be flanked by hydroxycarboxylic acids such as lactic acid, e.g., polyethylene glycol. Preferred monomers may be biodegradable, biocompatible, and non-toxic, and may also be at least somewhat elastic after crosslinking or curing. Crosslinkable monomers having amine groups may be, for example, polyethyleneimines, which may have a selectable degree of branching and molecular weight.
[0038] Macromers generally have a bioinert, water-soluble core. When the core is a water-soluble polymer region, the polymers that can be used include: polyethers, e.g., polyalkylene oxides, e.g., polyethylene glycol ("PEG"), polyethylene oxide ("PEO"), polyethylene oxide-co-polypropylene oxide ("PPO"), co-polyethylene oxide blocks or random copolymers, poloxamers, e.g., Pluronic® F-127; and polyvinyl alcohol ("PVA"); poly(vinylpyrrolidinone) ("PVP"); poly(amino acids); polysaccharides, e.g., hyaluronic acid or cellulose and their derivatives; dextran and proteins, e.g., albumin. Based on extensive experience with existing pharmaceuticals, polyethers and more specifically poly(oxyalkylene) or poly(ethylene glycol) or polyethylene glycol are particularly preferred. Hydrogels formed with macromers with longer crosslinking distances have been determined to be generally softer, more compliant, and more elastic. Therefore, in the polymer of Patent No. 566, increasing the length of the water-soluble segment, e.g., polyethylene glycol, tends to increase elasticity. The molecular weight of the hydrophilic macromer core, e.g., polyethylene glycol macromer core, may be in the range of about 5,000 to about 500,000 for the desired application, about 7,500 to about 100,000 in further embodiments, about 10,000 to about 50,000 in some embodiments, and about 15,000 to about 40,000 in other embodiments. Molecular weight (mass) as used herein may be in Daltons or molar mass - grams / mol (in either case assumed to be in the presence of natural isotopes), which are conventional units, and in polymers, molecular weight is generally reported to be the average, if there is any distribution of molecular weight. Those skilled in the art will recognize that additional ranges beyond those specified above are conceivable and within the scope of this disclosure.
[0039] Generally, monomers that provide electrophilic functional groups are macromers. Monomers that provide amine functional groups may be macromers or small molecule crosslinkers. Macromers having amine functional groups may fall within the molecular weight ranges specified in the preceding paragraph for macromers having electrophilic functional groups. Somewhat optionally, small molecule crosslinkers are specified herein to have a molecular weight of 4500 or less, and if the molecular weight is greater than 4500, they may be considered macromers. Therefore, the molecular weight of small molecule crosslinkers may generally be 100 to about 4500, in further embodiments about 200 to about 2500, and in further embodiments about 225 to about 1500. Those skilled in the art will recognize that additional ranges of crosslinker molecular weights beyond those specified above are conceivable and within this disclosure. When the core is substantially a small molecule, various hydrophilic functionalities can be used to make the precursor water-soluble. For example, water-soluble functional groups such as hydroxyl, amine, sulfonate, and carboxylate can be used to make the precursor water-soluble. Furthermore, although the N-hydroxysuccinimide ("NHS") ester of subaric acid is insoluble in water, adding a sulfonate group to the succinimide ring can make the NHS ester of subaric acid water-soluble without significantly affecting its reactivity to amine groups.
[0040] biodegradable bond When biocompatible crosslinked polymers are desired to be biodegradable or absorbable, one or more precursors having biodegradable bonds between their functional groups may be used. The biodegradable bonds may also optionally function as part of one or more water-soluble cores among the precursors. Alternatively, or in addition to this, the functional groups of the precursors may be selected such that the reaction products between them result in biodegradable bonds. With respect to each method, the biodegradable bonds may be selected such that the resulting biodegradable biocompatible crosslinked polymer degrades or is absorbed within a desired timeframe. Generally, biodegradable bonds are selected to degrade into non-toxic products under physiological conditions.
[0041] Biodegradable bonds can be chemically or enzymatically hydrolyzable or absorbable. Enzymatically hydrolyzable biodegradable bonds useful for explanation include peptide bonds that can be cleaved by metalloproteinases and collagenases. Biodegradable bonds useful for further explanation can be functional groups on core polymers and copolymers, such as hydroxycarboxylic acids, orthocarbonates, anhydrides, lactones, amino acids, carbonates, phosphonates, or combinations thereof. In the exemplary embodiments, the biodegradable bond is a hydroxycarboxylic acid moiety adjacent to the electrophile used for crosslinking.
[0042] Functional groups and crosslinking reactions Crosslinking reactions are generally designed to occur in vivo in aqueous solutions surrounded by physiological conditions, where the hydrogel reaction takes place in a transient local environment. Therefore, crosslinking reactions occur "in situ," that is, in localized areas such as the bodies of living animals or organs or tissues of the human body. Due to the in situ nature of the reaction, crosslinking reactions can be designed to avoid releasing undesirable amounts of heat during polymerization. Crosslinking times for desired treatments are described above. Some functional groups, such as alcohols or carboxylic acids, do not usually react with other functional groups, such as amines, under physiologically acceptable pH levels (e.g., pH 7.2–11.0, 37°C). However, such functional groups can be made more reactive by using activating groups, such as N-hydroxysuccinimide or derivatives thereof. Several methods for activating such functional groups are known in the art. Suitable activating groups include carbonyl diimidazole, sulfonyl chloride, aryl halide, sulfosuccinimidyl ester, N-hydroxysuccinimidyl ester (NHS), succinimidyl ester, epoxide, aldehyde, maleimide, and imide ester. N-hydroxysuccinimidyl or N-hydroxysulfosuccinimidyl groups are desirable for crosslinking proteins or amine-functionalized polymers, such as amino-terminated polyethylene glycol ("APEG"), because they have been shown to be acceptable in medical implants from the long-term use of approved products.
[0043] Other functional groups used for crosslinking are generally amines. Amines are weak bases, and the pKa of protonated amines depends on the molecule. Protonated amines are generally not suitable for nucleophilic substitution. Therefore, the precursor solution may be at a pH suitable for substantially maintaining protonated amines before being combined with the starting solution. This pH adjustment can maintain the precursor solution so as not to crosslink prematurely. Suitable small molecule amine precursors include lysine molecules and their oligomers. Specific small molecule amines include, for example, lysine, diridine, trilidine, tetralysine, pentharidin, and mixtures thereof. Lysine amines are generally protonated at physiological (near-neutral) pH values. The use of a small molecule crosslinking agent for one precursor may result in a relatively low-viscosity blend precursor before extensive crosslinking, allowing the blended hydrogel precursor to be delivered through a thin catheter while crosslinking is initiated and the fluid conforms to the shape of the uterine cavity, after which relatively rapid crosslinking in the presence of an accelerator leads to stabilization of the hydrogel in the uterus for an appropriate period. Because the precursor blend flows across the tissue, the hydrogel formed during the crosslinking process will match some deviation from the shape of small features of the tissue, such as ridges, gaps, and surface smoothness, but a perfect match is not required.
[0044] While mixed precursors are reasonably stable, their stability time is not long in terms of product distribution. Therefore, aqueous solutions of NHS-based crosslinkers and functional polymers can be prepared immediately before the crosslinking reaction, due to the reaction of NHS groups with water. For example, two separate vials of electrophile and nucleophile can be combined and placed in a syringe tube. The expression "pot life" can refer to the time from mixing. A longer "pot life" can be obtained by keeping these solutions at a lower pH. Generally, premixed precursors can be kept at a pH in the pH units of about 3.5 to about 6.5, about 3.75 to about 6.3 in some embodiments, and about 4 to about 6.2 in further embodiments. Generally, a longer pot life is associated with lower pH values across these ranges. These solutions are generally buffered to maintain the solution at a suitable pH value until mixed with the accelerator solution. Suitable buffers include, for example, phosphate buffers and / or citrate buffers. Suitable buffers may include biological buffers, such as those sold by Sigma Aldrich (https: / / www.sigmaaldrich.com / US / en / technical-documents / protocol / protein-biology / protein-concentration-and-buffer-exchange / buffer-reference-center). The total buffer salt concentration of the precursor solution may be about 2 mM to about 500 mM, about 5 mM to about 300 mM in further embodiments, about 7 mM to about 150 mM in other embodiments, and about 10 mM to about 100 mM in some embodiments. pH adjustment can be achieved by appropriately adding a strong acid or base to obtain the target pH. A reasonable pot life is easily achievable using the reagents described herein. A suitable pot life may be at least about 5 minutes, at least about 10 minutes in some embodiments, and about 12 minutes to about 10 hours in other embodiments. Those skilled in the art will recognize that additional ranges of pH, buffer concentration, and pot life time are possible and within the scope of this disclosure, as specified above.
[0045] The resulting crosslink density of biocompatible crosslinked polymers is controlled by the total molecular weight of the crosslinking agent and functional polymer, as well as the number of functional groups available per molecule. Lower molecular weights between crosslinks, such as 600 Da, result in a much higher crosslink density compared to higher molecular weights, such as 10,000 Da. Functional polymers with higher molecular weights can be used to obtain more elastic gels.
[0046] The crosslinking density can also be controlled by the total solids percentage of the solution of the crosslinking agent and functional polymer. Increasing the solids percentage increases the probability that electrophilic functional groups will bond with nucleophilic functional groups before inactivation by hydrolysis. Yet another way to control the crosslinking density is by adjusting the stoichiometry of nucleophilic functional groups to electrophilic functional groups. A 1:1 ratio leads to the highest crosslinking density. Generally, as time passes, the hydrogel completes curing, and the available crosslinking sites form crosslinks. If electrophiles and nucleophiles are provided in equal equivalent amounts, it can be expected that almost all functional groups will form crosslinks after total curing. Equal numbers (or reaction equivalents) of two types of active ingredients provide the highest crosslinking density. If different ratios of functional groups are used, the properties of the cured hydrogel may differ slightly accordingly. The crosslinking density can depend on the number of functional groups on the precursor molecule, as well as the ratio of the precursor molecules. Non-stoichiometric ratios of electrophiles and nucleophiles can be used to alter the crosslinking density if necessary. In some embodiments, the ratio of electrophilic to nucleophilic functional groups may be 0.8:1.0 to 1.0:0.8. Those skilled in the art will recognize that additional ranges beyond these explicitly stated ranges are conceivable and within the scope of this disclosure.
[0047] The solid content of the blended precursor solution can affect the properties of the resulting hydrogel and the ability of the precursor solution to fill the target space before crosslinking. If the solid content is too low, the hydrogel may be more susceptible to dilution effects from the fluid present in the space during delivery of the precursor solution. Even when the space is drained, a considerable amount of residual fluid may remain. Dilution effects can suppress desired space filling, lead to unreproducible results, and result in incomplete crosslinking, thus resulting in a low-modulus hydrogel implant. Excessively high solid content can lead to a precursor solution that crosslinks too rapidly and has a higher viscosity than desired, which can lead to applicator clogging and / or incomplete filling of the target space. Note that viscosity changes rapidly due to the fast gelation time, and once gelled, viscosity is essentially infinite. Generally, the solids content of the blend precursor solution delivered from the applicator is about 3 wt% to about 20 wt%, in further embodiments about 3.5 wt% to about 18 wt%, and in other embodiments about 3.75 wt% to about 16 wt%. Those skilled in the art will recognize that additional ranges beyond those specified above are conceivable and within the scope of this disclosure.
[0048] To achieve the target solids percentage, the two precursor solutions can, in principle, have a selected volume ratio. Generally, it is easiest to use equivolutes of the precursor and accelerator solutions, as this allows for corresponding equivolute and consistent delivery using syringes or other reservoirs. Nevertheless, the volume ratio and concentration can be adjusted to produce the same mixed concentration. Based on the selected solids percentage, desired volume, and volume ratio, the precursor solution concentration will be determined accordingly.
[0049] In electrophilic macromers or macromers having amine groups, the polymer may have multiple arms, each having terminal functional groups suitable for crosslinking. As described above, polyethylene glycol (PEG)-based macromers are established hydrogel precursors, and the core compounds are commercially available. PEG is also known in the industry as polyethylene oxide (PEO), and these names are interchangeable. PEG cores can have 3, 4, 5, 6, 7, 8, 9, 10 or more arms, and PEG with 4 arms (4A) and 8 arms (8A) are favorable degrees of branching. Macromers may also have a selected molecular weight, and a preferred range may be 10,000 Da (10 kDa) to 100,000 Da (100 kDa).
[0050] Generally, precursors (electrophiles and nucleophiles) are shipped in separate sterile vials. At an appropriate time in the procedure, for example, at the beginning of the procedure, these are mixed and placed in a syringe. Various forms of vials and other sterile components may be provided to facilitate this process. Pot life can be appropriately tracked depending on the expected time of use.
[0051] Accelerator solution In some embodiments, the crosslinking reaction may proceed more slowly under neutral conditions, but the reaction can be accelerated by adding an accelerator, such as a basic buffer, to allow it to occur over a desired time frame. Therefore, in hydrogels of particular interest herein, suitable buffers are close to neutral pH but somewhat basic, and include, for example, borates, phosphates, citrates, bicarbonates, CHES (N-cyclohexyl-2-aminoethanesulfonic acid), TAPS ([tris(hydroxymethyl)methylamino]propanesulfonic acid), bicine (2-(bis(2-hydroxyethyl)amino)acetic acid), tris (tris(hydroxymethyl)aminomethane), tricine (N-[tris(hydroxymethyl)methyl]glycine), CAPS (N-cyclohexyl-3-aminopropanesulfonic acid), CABS (C 10 H 21 NO3S), CAPSO (C9H 19It may contain NO4S, etc. The selected hydrogel precursor may be initially mixed to have a pH close to neutral to slightly acidic, resulting in slow crosslinking until mixed with the accelerator buffer.
[0052] Mixed buffers may be particularly desirable in accelerator solutions. Mixed buffers have been shown to extend the range of buffering capacity compared to individual buffers. Mixed buffers in accelerator solutions can yield a desired basic pH value, but then transition to a more neutral pH value after crosslinking is complete. Thus, the pH is maintained to complete crosslinking, but with a more moderate buffering capacity. Generally, one of the buffers in the mixture has a relatively high pKa, e.g., above 9, such as borate or CHES, while another buffer has a more neutral pH, such as phosphate or citrate. The relative amounts of two or more buffers are not particularly limited as long as the desired pH value is achieved. Total buffer concentration ranges for some embodiments are given below. In some embodiments, the weight ratio of the more neutral buffer to the more basic buffer may be about 0.05 to about 2.5, in further embodiments about 0.2 to about 2.25, and in some embodiments about 0.25 to about 2. Those skilled in the art will recognize that additional ranges beyond those expressed are conceivable and within the scope of this disclosure.
[0053] The preferred crosslinking time varies depending on the application. In most applications, the crosslinking reaction resulting in gelation occurs within approximately 5 minutes from the start of delivery, within approximately 1 minute in some embodiments, and within approximately 2 to 30 seconds in further embodiments. Those skilled in the art will recognize that additional ranges of gelation times beyond those specified above are conceivable and within the scope of this disclosure. These gelation times do not necessarily correspond to sufficient crosslinking that may occur over longer periods, and the gelation time corresponds to the point at which the hydrogel reaches a crosslinking point where it is no longer fluid. The crosslinking time in situ systems is a combination of several factors, including the relative concentration of the reactive precursor, the molar ratio of the reactive ends, the temperature, and the resulting pH after mixing. In some embodiments, sufficient crosslinking may occur after approximately 10 minutes, and in further embodiments, after approximately 15 minutes.
[0054] The gelation time can be altered by changing the pH, temperature, and buffer salt concentration of the “accelerator” portion of the in-situ system. In one embodiment, the pH range used to accelerate the system is approximately 7–12. In further embodiments, the pH range is approximately 8–11, in some embodiments it is within a pH range of approximately 9–10.5, and in further embodiments it is within a pH range of approximately 9.5–10.25. In one embodiment, the total accelerator buffer salt concentration is approximately 50 mM–1.5 M. In some embodiments the buffer salt concentration is approximately 100 mM–1 M, and in further embodiments it is approximately 150 mM–700 mM. Those skilled in the art will recognize that additional ranges of pH and concentration beyond the specific ranges described above are conceivable and within the scope of this disclosure.
[0055] A delivery system for forming hydrogel implants in situ. The delivery systems taught herein provide desired functionality for polymer delivery. Specifically, applicators may incorporate designs in which compositions from separate syringes are actively mixed and then directed into a thin tube or catheter. For transcervical delivery, specific applicators are described to provide convenient, accurate, and reproducible delivery. Further details of this device are provided in application 792 cited above. Alternative designs for laparoscopic polymer delivery are also described.
[0056] Referring to Figure 1, a delivery system useful for explanation, constructed according to the principles of the protocol herein, is described. The delivery system 100 includes a single-lumen catheter 108 having a proximal end 110 and a distal end 101. The proximal end 110 is attached to a Y-connector 112 through a fixture 111, for example, a standard Luer-lock fixture. The Y-connector 112 may contain, for example, a static mixing element within a tubular segment 113. The catheter 108 has an installation tip 102 at its distal end 101. In some embodiments, the outflow limiter 106 is adjustable, for example, slidable along the catheter 108, and adjusts the length of the distal catheter segment 104 of the outflow limiter 106. As shown in Figure 1, the length of the catheter 108 from the distal end of the installation tip 102 to the proximal end of the outflow limiter 106 can be about 5 cm to about 15 cm. In some embodiments, the length can be about 7 cm to about 10 cm. Similarly, as shown in Figure 1, the length of the catheter from the proximal end of the outflow limiter 106 to the proximal end of the attachment 111 can be approximately 4 cm to about 20 cm. In some embodiments, the length can be approximately 7 cm to about 9 cm. Those skilled in the art will recognize that the selected length of the catheter, as well as the presence and / or position of the outflow limiter, is generally subject to a variety of factors, such as the patient's anatomical structure, application conditions, and physician's preference, and that additional ranges of values beyond those specified above are conceivable and within the scope of this disclosure. For example, a physician may select a longer catheter in a laparoscopic procedure than in a transvaginal procedure, and this preference can be accommodated by using a longer catheter length while independently maintaining a medically appropriate length of catheter segment 104, which can be adapted from more specific teachings for cervical approaches by those skilled in the art. With regard to commercially available devices, various catheter lengths that can be connected to the attachment 111 are generally available for selection by healthcare providers, but in some embodiments described below, the length is adjustable so that the same components can be used to provide different lengths from the outflow limiter to the distal end.The outflow limiter 106 may have a conical shape as shown in the figure, or other shapes, and functions as a backstop or flow limiter to prevent excessive material from flowing out during the application of the hydrogel, and to guide the medical personnel to position themselves in the desired location. Mixing of the first solution 114 and the second solution 116 occurs within the Y-connector 112. The Y-connector 112 may include a static mixing element having a flow-altering baffle to facilitate proper mixing of the solutions, either within its outflow channel or within a separate section of the tubing segment 113 connected to the Y-connector. The Y-connector 112 has a fitting 111 for attaching the catheter 108, such as a Luer connector, and connections to syringes 115, 117, which may be retractable or not. The first solution 114 is generally a mixture of the first and second precursors formed at appropriate time points, where the reaction proceeds without accelerators and, respectively, does not occur to undesirable amounts within the relevant time scale, and the second solution is generally an accelerator / catalyst. Syringes 115 and 117 are generally held by a molded syringe holder 118, etc., to allow for convenient handling by healthcare professionals during use. An optional plunger cap 120 may maintain an optional fixed ratio of solution delivery ratio. If the inner diameters of syringes 115 and 117 are the same, the movement of the plunger cap 120 delivers volumes in a 1:1 ratio, but the inner diameters may be selected to result in different volume ratios if necessary. The outer diameter of syringes 115 and 117 may or may not follow the inner diameter, depending on the thickness of the syringe wall.
[0057] The delivery system 100 and its components may be made from a wide variety of materials that are sufficiently flexible and biocompatible, and different components may be assembled from materials suitable for those components. Some components may be readily fitted from commercially available parts. For example, polyethylene, nylon, polyvinyl chloride, polyether block amide, polycarbonate, polyurethane, polyolefin, polysiloxane, and other similar materials are preferred. In some embodiments, the delivery system includes a soft installation tip material to reduce trauma to the uterine surface during insertion and injection of the mixed fluid, and the materials of the installation tip are further described below.
[0058] Figure 2 is a partial view of a basic tip 126 for the placement tip 102 (see Figure 1) of catheter 108. The tip 126 has an open end for a cylindrical catheter. Catheter 108 may be configured to have a placement tip 102 provided with one or more side ports and / or one or more terminal outlets. One or more side ports and / or one or more terminal outlets may be configured to facilitate uniform delivery of a mixed fluid into the uterine cavity. The placement tip 102 is generally configured to be flexible and non-traumatic during use, and preferred materials are described below.
[0059] Figure 3 shows the uterine cavity 150, placement tip 166, internal os 154, cervical canal 158 with a length of approximately 4 cm, external os 162, cap element 170, and catheter 174. Generally, in a particular patient, the healthcare provider knows with reasonable accuracy the anatomical structure of the patient's uterus with respect to the length of the uterus and cervical canal, and the closure with the catheter can be adjusted to result in a specified distance from the posterior uterine lining to the catheter tip. The distance from the catheter tip to the posterior uterine lining after catheter placement can be about 0.25 cm to about 2.0 cm, and in further embodiments, about 0.35 cm to about 1.25 cm. A uterine sounding instrument may be used to estimate the distance using conventional procedures, and the sounding instrument may be held next to the outflow limiter to adjust the position of the cap. Those skilled in the art will recognize that additional distances beyond those specified above are conceivable and within the scope of this disclosure.
[0060] Figure 4 shows various embodiments of a cap element 109 that is shaped to serve as a backflow prevention device or cervical cap to prevent excess material from flowing out during hydrogel system fluid delivery, and as a reference guide for the placement of the installation tip 102. In this regard, the cap element 109 of the outflow limiter 106 may be highly curved overall, without sharp edges, and have a radially widened diameter compared to the catheter 108. Figure 4 shows (A) conical, (B) teardrop, (C) oval, (D) spherical, (E) flattened hemispherical, and (F) dome-shaped cap elements. Embodiments with a dome-shaped cap element may be used to provide a concave seal against the exocervix. The outflow limiter design may be selected to perform the desired function of sealing the cervical canal 158. Generally, such an object may be circular, conical, or have one or more angled faces, ensuring a secure and tight fit within the outer opening into the cervix, and allowing for complete coating of the uterine lumen and at least the inner portion of the cervix when the hydrogel has solidified sufficiently to avoid loss in the cervix, by stabilizing the hydrogel within the enclosed volume, and allowing for filling with hydrogel, if necessary, like a gently pressurized tamponade. Thus, the cap element 109 may have a radial diameter of about 5 mm to about 1.5 cm with respect to the catheter axis, and a length of about 2 mm to about 4 cm, and in some embodiments about 4 mm to about 3 cm along the catheter axis. Those skilled in the art will recognize that additional ranges within the specified dimensional ranges are conceivable and within the scope of this disclosure. The cap element 109 may be formed from any suitable material, such as polymers, for example, polymers suitable for catheters and implantation tips.
[0061] The attachment tip 102 preferably provides a non-traumatic structure to the patient, which may be characterized by softness and flexibility. In some embodiments, the non-traumatic tip may be formed from an elastomer, such as silicone rubber, rubber, polyisoprene, butyl rubber, or a mixture thereof. In further embodiments, the non-traumatic tip may be a second material to the main catheter shaft material, which is cojoined at the distal end by high-frequency welding, melting, gluing, or other known attachment methods. In other embodiments, the non-traumatic tip includes a coating added to the end by attachment of a different material, or an overlay of a co-extruded soft, flexible material. The materials of the non-traumatic tip may be characterized with respect to their softness using Shore durometer values, and the Shore hardness values may range from 20 to 80, and in further embodiments, from 50 to 70 on the scale. In embodiments where a transcervical access system may be used to extract fluid, a catheter with a harder tip may be used. Those skilled in the art will recognize that additional durometer values beyond those specified above are conceivable and fall within the scope of this disclosure.
[0062] Figure 5A shows an embodiment in which the catheter assembly 105 has a catheter 192 and an outflow limiter 106. The outflow limiter 106 includes a cap element 186 and a tubular member 188 proximal to the cap element 186. The tubular member 188 is supported by the catheter during infusion and is less flexible overall than the distal portion of the catheter 192 of the cap element 186. Figure 5A shows the assembled device, while Figure 5B shows the separated catheter 192 and outflow limiter 106. The catheter 192 includes a connector or hub 194 and the tubular element 196. The length of the catheter 192 is designed to be inserted into the uterine cavity with the cap element 186 in contact with the external opening into the cervix, called the external or external os. The tubular member 188 may have an adjustable position when assembled to match the overlap of all or part of the length of the tubular element 196 from the cap element 186 to the connector 194. Furthermore, the tubular element 196 may be uniform or non-uniform along its length with respect to its structure and / or composition. As described above, the catheter tip may be very soft to avoid tissue damage during hydrogel infusion, however, a very soft polymer may make applicator handling more difficult if incorporated along the entire length of the tubular element 196. In some embodiments, the tubular element 196 includes a distal port 184, including the tip in some embodiments, and a proximal portion 183 that is harder than the distal portion 185, indicated by a dashed line for dividing these regions. Optional positions for separating the harder proximal region are further described below. The proximal portion 183 may be formed from a section of tubing that covers and secures the upper side of the catheter, a change in the catheter material, and / or thickening of the catheter wall. Embodiments with a more rigid proximal section 183, as shown in Figures 5A and 5B, provide the user with greater stability when instrumenting the device in the cervix.
[0063] Referring to Figure 5A, the proximal end of the cap element 186 is attached to a tubular member 188 to provide an outflow limiter 106, as shown in the separated configuration in Figure 5B. In the assembled configuration of Figure 5A, the tubular member 188 externally reinforces at least a portion of the length of the catheter 192 proximal to the cap element. The tubular member 188 also allows the outflow limiter 106 to be grasped to facilitate the procedure. The length of the tubular member 188 can be about 5 cm to about 20 cm, about 6 cm to about 19 cm in further embodiments, and about 7 cm to about 18 cm in some embodiments. Those skilled in the art will recognize that additional ranges of lengths beyond those specified above are conceivable and within the scope of this disclosure. The outflow limiter 106 is typically engaged to cover a portion of the catheter 192, as shown in Figure 5A, for insertion of the catheter into the patient's body. The outflow limiter 106 allows the user to adjust the position of the cap element 186 to give a distal catheter length value within the ranges specified above. In some embodiments, the tubular member 188 can introduce frictional interaction with the catheter surface internally to prevent unintended movement of the outflow limiter 106. The user can set the position of the outflow limiter 106 and maintain its position along the catheter 192 by avoiding unintended sliding of the tubular member 188. In other embodiments, the position of the cap element 186 can be adjusted and / or maintained between the catheter 192 and the outflow limiter 106 by a clip, ridge, etc., that engages with a flange on a pair of elements. Since the cap element 186 is fixedly attached to the tubular member 188, the design of the tubular member 188 prevents accidental loss of the cap element 186.
[0064] Figure 6A shows a specific embodiment of a catheter assembly 193, including a catheter 197, an outflow limiter 195, and a connector 194. Figure 6B shows a magnified cross-section of the portion of Figure 6A indicated by a dashed rectangle. Figure 6C shows an exploded view of the catheter assembly 193. The catheter 197 includes a core tube 191 and an overtube 192, both of which engage with and are secured to a connector 194, which may be a female Luer connector or the like. When assembled, the catheter 197 has a distal section with a smaller diameter than the proximal section due to the presence of the overtube. The connector 194 can be secured by adhesive, thermal bonding, crimping, or a combination thereof, as long as the central lumen remains open. The overtube 192 can be held in place by simply securing it to the connector 194, or similarly by thermal bonding, adhesive bonding, or other preferred techniques to the core tube 191. The overtube 192 may provide rigidity to the proximal end of the catheter 197 and provide frictional engagement to the outflow limiter 195. The overtube 192 may be made of a thicker and / or harder material than the core tube 191. In some embodiments, the length of the overtube 192 may be about 5 cm to about 20 cm, in further embodiments about 6 cm to about 19 cm, and in some embodiments about 7 cm to about 18 cm. Those skilled in the art will recognize that additional ranges of lengths beyond those specified above are conceivable and within the scope of this disclosure.
[0065] Referring to Figure 6C, the outflow limiter 195 includes a conical cap element 198 and a tubular member 199. The conical cap element 198 is attached to the tubular member 199 by adhesive or other suitable fastening modality. Referring to Figure 6B, the conical cap element 198 has a cavity with a distal diameter 200, a proximal diameter 201, and a stepped reduction section 202. The stepped reduction section 202 reduces the diameter of the cavity within the conical cap element. The stepped reduction section 202 provides a mechanical stop to prevent the outflow limiter 195 from sliding in the direction more proximal to the overtube 192. The conical cap element 198 has a narrow stenosis at its distal end, which frictionally connects to and grips the catheter 197, thereby restricting the movement of the outflow limiter 195 along the catheter. Therefore, although its position can be selected by a medical professional, friction with the overtube 192 can itself provide the desired limitation on the relative movement of the outflow limiter 195.
[0066] treatment The hydrogel applicators in their various embodiments are particularly effective for delivering the various hydrogel systems described herein.
[0067] Figure 7 illustrates the procedure for transcervical placement of a hydrogel into the uterus. A vaginal speculum 220 is inserted into the vagina 222 to dilate it. The placement tip 228 of the catheter 230 is guided into the uterus 226 through the vagina 222 and cervix 224. The placement tip 228 is flexible at its distal end, thereby allowing it to adapt to the shape of the uterus 226 and reducing the risk of trauma. A cap element 232 is positioned at a distance from the distal end of the placement tip 228 to limit the insertion depth of the placement tip 228 into the uterus. In one embodiment, the cap element 232 is adjusted to an appropriate distance from the distal end of the placement tip 228 so that the physician can comfortably manipulate the syringe when the placement tip 228 is positioned with the cap element 232 adjacent to the opening into the cervix, with the tip appropriately spaced away from the posterior wall of the uterus. In some embodiments, the cap element 232 is part of an adjustable flow limiter. In some embodiments, the catheter 230 with the cap element 232 is placed in the uterus 226 by a physician with the syringe assembly 233 not attached, and then in the next step, the syringe assembly 233 is attached to the catheter 230, for example, via a Luer connector 226. In some embodiments, a standard empty syringe may first be placed on the Luer connector 226 to draw fluid from the uterine cavity, and following the completion of the removal of this fluid, the syringe may be removed and replaced with the syringe assembly 233. Such a stepwise procedure may facilitate insertion and use by a single user. As described above, in suitable embodiments, the cap element may be adjusted and / or fixed in a position along the length of the catheter by manually adjusting the proximal end of the flow limiter. When positioned adjacent to the opening to the cervix, the cap element 232 may function to seal the uterine cavity by being completely filled and coated with hydrogel. This provides physicians with means to prevent leakage of the hydrogel injected at the external cervical os. Furthermore, in some embodiments, the cap element 232 may be further adjusted to fit the cervix by filling it with a fluid, such as a gas or liquid, if it is inflatable.
[0068] In any embodiment of the cap element, distance markers along the catheter may help position the cap element 232 at a suitable location for placement. After the placement tip 228 and the cap element 232 are positioned as desired, the syringe assembly 233 is used to introduce one or more precursors and, where appropriate, an accelerator solution into the Y-connector (optionally including a static mixing element) to provide a mixed hydrogel-forming composition before entering the catheter 230. The mixed fluid remains sufficiently fluid until they exit the placement tip 228 and subsequently further polymerize and / or crosslink to form a hydrogel 238 that occupies the uterine cavity. In some embodiments, the injection is continued without stopping until completion to prevent occlusion of the catheter 230 and / or placement tip 228 due to hydrogel formation. In some embodiments, the syringe assembly 233 includes a plunger cap to facilitate the appropriate volume ratio dispensed from two syringes.
[0069] Outline of hydrogel compositions and embodiments of treatments particularly suitable for applications of particular interest are provided below. In these embodiments, it is assumed that two hydrogel precursors (PEG-based precursor & crosslinking agent) are pre-mixed, and the time from mixing to delivery is referred to as the pot life. The two precursors may be provided in a suitable container to facilitate their mixing. One of the precursors, or a separate solution to be mixed with the precursors, may contain a visualizing agent. The mixed precursors, with an optional coloring agent, are placed in a syringe or the like. Based on the selected precursor, crosslinking of the precursors occurs slowly at the pH of the mixed precursors. A second syringe contains a buffer, which is a generally clear solution, and this is mixed with the precursors to begin accelerating crosslinking during the delivery process. This discussion relates to steps 1 and 2 below.
[0070] The following delivery methods may be conveniently used to form an intrauterine hydrogel barrier: 1) Mix the diluent (blue) with PEG and dissolve it. 2) Withdraw the PEG solution back into the syringe and add it. 3) Attach a Y-type connector to each syringe. 4) Load the clear and blue syringes into the syringe holder. 5) Place the plunger cap on the end of the syringe. Set. 6) Position the flow limiter at the correct depth of the catheter shaft, ensuring that when the flow limiter contacts the cervical external os, the distal catheter tip is approximately 1 cm below the uterine cavity floor. 7) Attach the syringe equipped with a Y-type connector to the applicator. 8) Before 60 minutes have elapsed since step 1, insert the catheter into the uterus via the cervix until the flow limiter touches the external os. 9) Continuously deliver the hydrogel by gently pressing the flow limiter against the cervix and pressing the applicator cap with relatively constant force until the syringe is empty. Since most uterine cavity sizes do not require the entire amount of hydrogel, you may see the colored fluid leaking from the cervix where the flow limiter is positioned and slightly resisting the flow. 10) Wait approximately 2 seconds, then gently remove the catheter.
[0071] Once the syringes are prepared, they can be attached to a Y-type connector using a standard connector, such as a Luer connector, as described in step 3 above. To facilitate delivery, the syringes are generally placed in a syringe holder (as described in step 4 above)) to allow for one-handed handling, and the plunger caps may be positioned to allow for simultaneous, uniform delivery of liquid from both syringes, possibly using one hand. The applicator tip can be inserted into the patient's body to the desired depth, which may be marked by an acorn or the like. If necessary, the applicator tip may be positioned before the syringe is fully prepared.
[0072] With the applicator tip in place, the uterine cavity may optionally be flushed to remove blood, fluid, and possibly other material remaining from the procedure. For example, a syringe containing a flushing solution such as buffered saline or other desired fluid may be attached to the connector of the applicator tip for flushing. While the use of the applicator tip may be preferable, flushing may be performed using a different channel, possibly before the applicator tip is positioned. Flushing may be performed with a selected amount of fluid or may be continued until the space appears to have been cleaned by the release.
[0073] When the hydrogel precursor is ready for delivery into the uterine cavity, the Y-connector can be attached to the connector on the applicator tip (step 7). In alternative embodiments, if the applicator tip is not used for flushing, the Y-connector can be attached to the applicator tip before placing the applicator tip into the patient's body. Thus, the hydrogel precursor is delivered into the patient's body (step 8). Since the syringe cap is generally pressed relatively continuously, excessive crosslinking does not occur within the applicator tip, but strict continuous delivery is not required. The delivery rate can be nearly constant, but again, this is not essential, or even desirable if the force for delivery changes as the cavity fills. In some embodiments, it is desirable to start the delivery of the hydrogel before a pot life of more than 60 minutes. In alternative hydrogel formulations, this time may be modified.
[0074] Fluid delivery may be continued until pressure from the uterus pushes back the acorn-shaped body. This pushback indicates that the uterine cavity is filled with fluid. Once the cavity is full, the injection is stopped. After stopping delivery, it is desirable to wait for a short period to allow crosslinking and gelation to occur. After waiting for an appropriate period, e.g., about 2 seconds and less than 5 minutes, the applicator tip is removed (step 10). In a sufficiently crosslinked state, the amount of hydrogel lost from the uterine cavity should be minimal, if any. The integrity of hydrogel delivery can be confirmed using ultrasound.
[0075] Figures 8 and 9 illustrate transcervical hydrogel delivery using various embodiments of the improved treatment based on the hydrogel system described herein, with Figure 8 relating to the use of a removable outflow limiter and Figure 9 relating to the use of both a removable outflow limiter and a cervical plug. These drawings are presented as procedure flowcharts, with the procedure flowing from top to bottom.
[0076] Referring to Figure 8, in this embodiment, the transcervical applicator takes the form of an applicator 250, which is shown with an outflow limiter 252 attached to a catheter 254 positioned to be inserted 260 into the uterus 258 in the uterine cavity 259, passing through the cervical outer os 256 and the cervical inner os 258. Following insertion 260, as shown in the second drawing of Figure 8, a cap element 255 is positioned at the cervical outer os 256 and the catheter 254 is in the uterine cavity 259. A hydrogel precursor is injected into the uterine cavity 264, filling the cavity with hydrogel 266. The catheter 254 is then removed 268, as shown in the fourth drawing of Figure 8, leaving the outflow limiter 252 with the cap element 255 at the cervical outer os 256. With the outflow limiter 252 removed, the last figure in Figure 8 shows the uterus 258 filled with hydrogel 266 extending beyond the internal cervical os.
[0077] Referring to Figure 9, the upper diagram shows an applicator 310 comprising an outflow limiter 312 and a cervical plug 314 distal to the cap element 315 of the outflow limiter 312, which is fitted over the upper side of a catheter 316 positioned to be inserted into the external os of the cervix into the uterus 320 in order to position the catheter tip in the uterine cavity 322. Following insertion 326, the second diagram of Figure 9 shows the tip of the catheter 316 in the uterine cavity 322 with the cervical plug 314 in the cervix and the cap element 315 positioned at the external os of the cervix. Following the injection of the hydrogel precursor 330, the third diagram of Figure 9 shows the hydrogel 332 in the uterine cavity 322 up to the cervical plug 314. Following the removal of the catheter 316 from the uterus 320 334, the hydrogel 332 fills the uterus, the cervical plug 314 is in place within the cervix, and the outflow limiter 312 is positioned with its cap element at the external os of the cervix. Following the removal of the outflow limiter 312 336, the last figure in Figure 9 shows the uterus 320 filled with hydrogel 332, with the cervical plug 314 still in place. In interuterine applications, the hydrogel system can be suitable for transcervical delivery, the final laparoscopic delivery in a laparoscopic procedure, or open procedures, generally used during the closing step of the procedure. The hydrogel can function as a material to reduce or eliminate tamponade and adhesion formation. The design of the properties of the hydrogel to facilitate these functions will be further described below, but the delivery procedure using an applicator will be described next.
[0078] Figure 10 shows a procedure in which hydrogel is placed in a body cavity 242, such as the pelvic cavity, laparoscopically. The placement tip 248 of the catheter 244 is placed into the body cavity 242 via a hysteroscopy channel, and the mixed fluid is delivered into the body cavity 242. As described above with respect to transcervical placement, the syringe system 250 may be attached after or during placement of the catheter 244. Other embodiments described above are also applied to laparoscopic placement of hydrogel. Similarly, open procedures may be adapted for hydrogel delivery to reduce or eliminate adhesions. For example, the open incision may be partially closed, followed by delivery of the hydrogel precursor, after which the closure of the incision may be completed.
[0079] As described in the examples below, transcervical delivery was observed to conformally fill the uterine space with hydrogel. The horns were filled up to the fallopian tube openings, while the fallopian tubes remained free of hydrogel. Similar results can be expected from laparoscopic or open procedures.
[0080] The length, inner diameter, outer diameter, and material of the catheter may vary depending on the access conditions. The catheter, including the implantation tip, should be appropriately sized to facilitate delivery, have a low profile, and cause an acceptable level of low trauma when inserted and advanced to the treatment site. In embodiments preferred for forming hydrogel implants in the uterus, the implantation tip has a distal outer diameter of about 1 mm to about 3 mm to allow delivery through the cervix. The proximal outer diameter of the catheter may be about 2 mm to about 6 mm, about 2.5 mm to about 5 mm in further embodiments, and about 2.5 mm to about 4.5 mm in even further embodiments. The catheter length from the distal tip to the connector may be about 14 cm to about 30 cm, about 15 cm to about 28 cm in further embodiments, and about 16 cm to about 26 cm in other embodiments. In some embodiments, the catheter OD needs to be practically small to reduce the size of the removal trajectory after cross-linked gel formation in the uterus. In other embodiments, the distal profile of the catheter to be positioned in the neck should be 9 Fr or less, 8 Fr or less in some embodiments, and 3 Fr to 7 Fr in further embodiments. Those skilled in the art will recognize that additional length and diameter ranges within the specified diameter ranges described above, such as 6 Fr, 5 Fr, and 4 Fr, are conceivable and within the disclosure. This reduces the need to withdraw the catheter during the injection event to prevent the barrier from passing through or being removed at the exit of the device.
[0081] Hydrogel deployment is often performed by groping without visualization, but visualization under ultrasound guidance can be enabled by adding a visualizing agent such as microbubbles, or by adding a radiopaque-inhibiting agent. These visualizing agents can be mixed with the precursor solution and / or covalently bonded to one or both precursors. One embodiment involves using a branched precursor having a covalently bonded radiopaque agent so that the hydrogel has a covalently bonded radiopaque agent when it is formed from a mixture of radiopaque-labeled precursors or a mixture containing the same. In some embodiments, a highly echogenic hydrogel may arise from gases from the headspace in the precursor syringe and / or from the precursor incorporated as microbubbles in the hydrogel. The ultrasound contrast agent can be increased or decreased by altering the headspace in the precursor syringe before gel placement.
[0082] Radiopaque agents can be attached to precursors by various methods. Some of these methods are described in U.S. Patent No. 7,790,141, which is incorporated herein by reference and includes radiopaque agents, precursors, and matrices; in case of any inconsistency, this specification shall prevail. Precursors described herein and in the references incorporated herein may be coated with one or more radiopaque agents. In the case of branched or multifunctional precursors, one or more of the available reaction sites may be left unreacted. Thus, an 8-arm precursor may have 1 to 8 functional groups available for covalent bonding to form a matrix, and 1 to 8 functional groups that are replaced by (or react with) a radiopaque agent. Examples of radiopaque agents include iodine-containing molecules, TIBs, phenyl ring compounds, such as 2,3,5-triiodobenzoic acid, 3,4,5-triiodophenol, erythrosine, rose bengal, 3,5-bis(acetylamino)-2,4,6-triiodobenzoic acid, and 3,5-diacetamido-2,4,6-triiodobenzoic acid.
[0083] Additional machine-assisted contrast agents may be used in addition to, or as an alternative to, radiopaque compounds. Such contrast agents include, for example, fluorescent compounds, ultrasound contrast agents, or MRI contrast agents (e.g., gadolinium-containing compounds). In some embodiments, suspended solid inorganic particulates, such as barium sulfate, titanium, and / or bismuth chloride, may be used to enhance both radiopaqueness and visibility under ultrasound. In some embodiments, hydrogel particles may be incorporated into the hydrogel composition. In some embodiments, the particle composition, particle concentration, and particle size may be adjusted to control the radiopaqueness and / or ultrasound contrast of the hydrogel composition. In some embodiments, the average particle diameter may be in the range of about 10 microns to about 500 microns. Particles with radiopaque agents may be blended with particles without radiopaque agents to create a group of particles with the desired radiopaqueness.
[0084] In embodiments of particular interest, the hydrogel composition has a coloring agent to facilitate visual observation, as will be further described in the description of the hydrogel. If necessary, the treatment space may be filled with or flushed with an inert solution such as saline to remove blood and other biological fluids from the treatment space before delivery of the hydrogel. The delivery system 100 in Figure 1 or the procedure in Figure 7 or Figure 10 may optionally include an additional lumen to allow such flushing fluid to exit the treatment space. Alternatively, a non-inert solution, such as a drug solution, may be delivered into the treatment space.
[0085] Properties of hydrogels The hydrogels described herein can generally be delivered by minimally invasive means, such as through small-diameter catheters. Hydrogel delivery systems combine two solutions, which are delivered as a blend and rapidly crosslink into a hydrogel. Therefore, the hydrogel is fully formed in situ after delivery. Hydrogels of particular interest generally begin as precursors that can react to form a gel upon crosslinking by nucleophilic substitution. Polymer precursors are described in detail above.
[0086] The conditions can be controlled using the applicator described above in relation to the delivery system to obtain crosslinking and gel formation suitable for the delivery process. Generally, crosslinking begins within the catheter of the delivery system but does not complete sufficiently to restrict flow from the catheter into the patient's body. The hydrogel can solidify sufficiently, remain in place for a suitable period, and crosslink sufficiently after the completion of the procedure.
[0087] Sometimes, it is useful to impart color to the hydrogel precursor by adding a coloring and visualizing agent before crosslinking. The visualizing agent can help visualize the arrangement of the hydrogel. For example, when filling a uterus, the visualizing agent helps distinguish the hydrogel from other fluids. Furthermore, the color of a colored hydrogel can provide information about the concentration of the precursor in the hydrogel or the degree of mixing of physiological fluids into the hydrogel. One embodiment of the present invention uses a biocompatible crosslinked polymer formed from the reaction of an electrophilic functional precursor with a nucleophilic functional precursor. The precursors are generally water-soluble, non-toxic, and bioacceptable.
[0088] In electrophilic-nucleophilic reaction systems, the precursor contains two or more electrophilic or nucleophilic functional groups, such that a nucleophilic functional group of one precursor can react with an electrophilic functional group of another precursor to form a covalent bond. If the precursor has three or more functional groups, the precursor molecule can participate in the crosslinking reaction, and generally, the hydrogel is crosslinked to a relatively high degree. Small molecule crosslinking agents generally have a solubility of at least 1 g / 100 mL in aqueous solution.
[0089] The hydrogel for use in patient tissue comprises water, a biocompatible visualization agent, and a cross-linked hydrophilic polymer that forms the hydrogel after delivery into the uterine cavity. The visualization agent can reflect light or emit light at wavelengths detectable by the human eye, allowing the user applying the hydrogel to observe the gel and estimate its thickness.
[0090] Hydrogels intended for placement in the uterus generally swell moderately, to a degree sufficient to facilitate space filling, but not to an excessive degree that would create uncomfortable pressure on the patient. In some situations, swelling may refer to a continuous change in volume or weight following the initial formation of a cross-linked, insoluble structure, in which case the timing is appropriately specified. The transition from a dry state to a hydrated state results in an increase in weight and generally some increase in volume, while the change from the initial state formed in aqueous solution to the state over time may or may not involve an increase in weight or volume over time, and may result in a decrease in some time windows.
[0091] The hydrogel for placement in the uterus swells moderately, to the extent that it swells enough to facilitate space filling, but not excessively so as to create uncomfortable pressure on the patient. In some embodiments, the swelling of the hydrogel can be less than 300 wt%, in further embodiments about 10 wt% to about 200 wt%, and in even further embodiments about 20 wt% to about 100 wt%. In alternative embodiments, the hydrogel may experience syneresis after initial formation, i.e., it may become smaller on a weight basis and generally smaller on a volume basis, which is conveniently referred to as negative swelling. Thus, the overall swelling can be about -25 wt% to about 300 wt%, in further embodiments about -15 wt% to 200 wt%, and in other embodiments about -10 wt% to about 100 wt%. Swelling (positive or negative) can generally be determined by the weight of the polymer after 24 hours of contact with an aqueous environment, with the aqueous solution of buffered saline absorbed by the polymer, relative to the weight of the polymer and the absorbed aqueous solution after crosslinking to an insoluble mass that forms after a few seconds. The hydrogel may be biodegradable so that the uterine space is cleaned after a suitable period, and the healing process does not release the hydrogel material itself. In some embodiments, the hydrogel is completely biodegraded in about 1 to 29 days, in further embodiments in about 3 to 21 days, and in further embodiments in about 5 to 14 days. In some applications, such as drug delivery, it may be desirable for the hydrogel to biodegrade over a longer period, e.g., 30 days or more. The hydrogel may also be selected to be soft enough to be gentle on tissues but not soft enough to be extruded from the uterus, making its survival in the cavity unpredictable. The survival of the placed hydrogel in the uterus is predicted to be related to the duration over which the modulus of the hydrogel exceeds a threshold range estimated to be about 1 kPa to about 10 kPa. Since expulsion force tends to vary from patient to patient, the modulus's time-dependent decay can be selected to produce a value favorable for retaining the hydrogel in the uterine cavity for most patients. Below this estimated range, the hydrogel is expected to have insufficient resistance to compressive forces to resist being removed from the uterus.Specifically, the initial Young's modulus of the hydrogel (evaluated for convenience 12 hours after initial gelation) can be approximately 13 kPa to 300 kPa, approximately 5 kPa to 250 kPa in further embodiments, and approximately 5 kPa to 200 kPa in further embodiments. Young's modulus is a measure of compressive force per unit area divided by the change in volume per unit volume. A gel stopper may be used to perform measurements using an Instron or alternative brand of compression instrument, where the stress / strain gradient is measured over the first 20% of compression. As shown in Example 3, gels prepared from the premixed precursor formulation showed higher initial modulus values and a slower modulus decline rate compared to gels prepared from the separated formulation. This result suggests that the premixed precursor formulation offers advantages over the separated formulation in terms of prolonging survival in utero. The premixed precursor hydrogel system also provides good dilution resistance and good space-filling properties during delivery. These advantages are particularly useful in privileged spaces, such as the uterus, where the slower diffusion of buffer salts from the placement site is theorized to contribute to the acceleration of hydrogel degradation. Those skilled in the art will recognize that additional ranges of swelling, degradation rates, and Young's modulus beyond those specified above are conceivable and are within the scope of this disclosure.
[0092] The preferred crosslinking time varies depending on the application. Gelation time can be evaluated in the laboratory. In most applications, the crosslinking reaction leading to gelation occurs within approximately 5 minutes from the start of delivery for gelation, within approximately 1 minute in some embodiments, within approximately 30 seconds or less in other embodiments, within approximately 1 to 20 seconds in further embodiments, and within approximately 1.5 to 15 seconds in further embodiments. Those skilled in the art will recognize that additional ranges of gelation times beyond those specified above are conceivable and within the scope of this disclosure. Once delivered into the uterine cavity, gelation evaluation is somewhat obscured by delivering fresh precursors over a timeframe spanning the gelation time. The objective is generally to have a gelation time that is sufficiently rapid to avoid excessive flow from the cervix and little to no flow into the fallopian tube, but with a gelatin time that is sufficiently slow to ensure the cavity is uniformly filled and the catheter does not become clogged. These gelation times do not necessarily correspond to a fully crosslinked state that can occur over a longer period; rather, the gelation time corresponds to the point at which the hydrogel is no longer fluid, which can be evaluated in vitro under controlled conditions. The crosslinking time may depend on a combination of several factors, such as the relative concentration of the reactive precursor, the molar ratio of the reactive ends, the temperature, and the resulting pH after mixing. The gelation time may be altered, if present, by one or more changes in the pH, temperature, or strength of the buffer salt in the “accelerator” portion of the in-situ system.
[0093] Natural polymers, such as proteins or glycosaminoglycans, such as collagen, fibrinogen, albumin, and fibrin, can be crosslinked using reactive precursor species having electrophilic functional groups. Natural polymers are proteolytically broken down by proteases present in the body. The precursors may have a biologically inert and water-soluble core. When the core is a water-soluble polymer region, suitable polymers that can be used include: polyethers, such as polyalkylene oxides, such as polyethylene glycol ("PEG"), polyethylene oxide ("PEO"), polyethylene oxide-co-polypropylene oxide ("PPO"), co-polyethylene oxide blocks or random copolymers, and polyvinyl alcohol ("PVA"); poly(vinylpyrrolidinone) ("PVP"); poly(amino acids); dextran, and proteins, such as albumin. Polyethers, and more specifically poly(oxyalkylene) or poly(ethylene glycol) or polyethylene glycol, can provide desired properties to hydrogels.
[0094] The synthetic polymers and reactive precursor species may have electrophilic functional groups, such as carbodiimidazole, sulfonyl chloride, chlorocarbonate, n-hydroxysuccinimidyl ester, succinimidyl ester, n-hydroxysulfosuccinimidyl ester, sulfosuccinimidyl ester, or mixtures thereof. In some embodiments of particular interest, the electrophilic functional group includes N-hydroxysuccinimidyl succinate (SS) esters, which provide a desired crosslinking rate for hydrogel formation and a hydrogel degradation rate following in vivo-formed hydrogel. The term "synthesis" means molecules not found in nature, such as polyethylene glycol. The nucleophilic functional group may be, for example, an amine, such as a primary amine, hydroxyl, carboxyl, and thiol. The primary amine may be the desired reactant with the NHS electrophile. In embodiments of particular interest, the polymer may have a polyalkylene glycol moiety and be polyethylene glycol-based. The polyethylene glycol-based polymer precursor may have a branched core to provide a selected number of arms that offer multiple crosslinking functional groups. Polymers also generally have hydrolytically biodegradable moieties or bonds, such as esters, carbonates, or enzymatically biodegradable amide bonds. Some such bonds are well known in the art and arise from α-hydroxy acids, their cyclic dimers, or other chemical species used to synthesize biodegradable products such as glycosides, dl-lactides, l-lactides, caprolactones, dioxanones, trimethylene carbonates, or copolymers thereof. In some embodiments, reactive precursor species may each have 2 to 10 nucleophilic functional groups, and corresponding reactive precursor species may each have 2 to 10 electrophilic functional groups.
[0095] In some embodiments, a hydrogel is selected and delivered to at least partially fill the uterus, and in embodiments of particular interest, the hydrogel substantially fills the uterus. Therefore, upon sufficient crosslinking, the hydrogel takes on a shape similar to the interior of the uterus. While filling the uterus, the hydrogel can form a coating on at least a portion of the intrauterine tissue. In some embodiments, the hydrogel substantially fills the uterus and comes into contact with substantially all of the tissue exposed within the uterus and cervix. The introduction of one or more fluid precursors or precursor solutions into the uterus, which may be adjusted to some extent based on swelling, to form a hydrogel with a volume essentially equal to the volume of one or more fluid precursors or precursor solutions, can come into contact with substantially all of the tissue exposed within the uterus, as the fluid conforms to the shape of the tissue. Nevertheless, it is recognized by those skilled in the art that even substantially complete contact can suffer from imperfections.
[0096] In some embodiments, the method is used to form a hydrogel on tissue until the color of the hydrogel indicates that a predetermined volume of hydrogel has been deposited on or within the tissue. Precursors are continuously introduced into the space until a suitable volume is deemed to have been achieved by the color of the material entering and flowing out of the space, as indicated by observing a visualizer placed in the flowing material. For example, two fluid precursors associated with a blue dye are introduced into and delivered into the uterus until the color of the material leaving the uterus indicates that unwanted fluid has been flushed out of the uterus and the uterus is substantially full of precursors.
[0097] Users may use a visualizing agent to view the hydrogel using an imaging device that detects a visually observable visualizing agent, such as a video camera used during surgical hysteroscopy, or with the human eye. A visually observable visualizing agent is an active substance that has a color detectable by the human eye. The feature of providing an image to an X-ray or MRI machine is not sufficient to establish its function as a visually observable visualizing agent. An alternative embodiment is a visualizing agent that may not normally be visible to the human eye, but which, when used in combination with a suitable imaging device, such as a properly equipped video camera, is detectable at different wavelengths, such as infrared or ultraviolet light.
[0098] The three-dimensional hydrogel structure may be resistant to expulsion from the uterine cavity, thus helping to separate the uterine wall and prevent the formation of scar bridges or adhesions. Over time, the hydrogel breaks down and is naturally expelled from the uterine cavity either by absorption into the body or, mostly, by release through the cervix and vagina.
[0099] In some embodiments, a hydrogel is selected and delivered to at least partially fill the uterus, and in embodiments of particular interest, the hydrogel substantially fills the uterus. Therefore, upon sufficient crosslinking, the hydrogel takes on a shape similar to the interior of the uterus. While filling the uterus, the hydrogel can form a coating on at least a portion of the intrauterine tissue. In some embodiments, the hydrogel substantially fills the uterus and comes into contact with substantially all of the tissue exposed within the uterus and cervix. The introduction of one or more fluid precursors or precursor solutions into the uterus, which may be adjusted to some extent based on swelling, to form a hydrogel with a volume essentially equal to the volume of one or more fluid precursors or precursor solutions, can come into contact with substantially all of the tissue exposed within the uterus, as the fluid conforms to the shape of the tissue. Nevertheless, it is recognized by those skilled in the art that even substantially complete contact can suffer from imperfections.
[0100] Visualizing agent Where advantageous, biocompatible cross-linked hydrogel polymers may contain a visualization agent to enhance their visibility during surgical procedures. Visualization agents are particularly useful when used in minimally invasive surgical procedures (MIS, e.g., laparoscopy) due to their high visibility on color monitors, among other reasons.
[0101] The visualization agent can be selected from a variety of non-toxic colorants suitable for use in medical implantable devices, such as FD&C BLUE dyes 1, 2, 3, and 6, indocyanine green, or colored dyes commonly found in synthetic surgical sutures. In some embodiments, green or blue is preferred because they have good visibility in the presence of blood or against a pink or white tissue background.
[0102] The visualization agent may be present in the accelerator solution, or both, together with a solution containing reactive precursor species. It may be advantageous to include a visualization agent equipped with an accelerator solution. The selected coloring substance may or may not be chemically bonded to the hydrogel. Additional visualization agents, such as fluorescent compounds (e.g., green or yellow fluorescence under visible light) (e.g., fluorescein or eosin), X-ray contrast agents for visibility under X-ray imaging equipment (e.g., iodine compounds), ultrasound contrast agents, or MRI contrast agents (e.g., gadolinium-containing compounds), may be used. The visualization agent may also be a bioactive agent suspended or dissolved in the hydrogel matrix, or, if present, a material used to encapsulate the bioactive agent.
[0103] Further visualization of the hydrogel implant can be achieved directly after injection using transvaginal ultrasound (TVUS). The presence and extent of the hydrogel filling the uterine cavity (including the endometrial cavity and the cervix visible on ultrasound) is hyperechoic immediately after injection due to the presence of some air trapped inside, and the areas where it fills the uterine cavity appear as echogenic (bright) spaces.
[0104] As mentioned above, visually observable visualization agents can be conveniently used in several embodiments. Light wavelengths of approximately 400–750 nm are observable to humans as color (RKHobbie, Intermediate Physics for Medicine and Biology, 2 nd (Ed., pages 371-373). Blue is perceived by the eye when it receives light with a wavelength of approximately 450–500 nm, and green is perceived at approximately 500–570 nm (Id.). Furthermore, since the eye can detect red, green, or blue, combinations of these colors can be used to mimic any other color simply by giving the eye the proportions of red, green, and blue that are perceived by the human eye as the desired color. As used herein, blue means the color perceived by the normal human eye when stimulated by a wavelength of approximately 450–500 nm, and as used herein, green means the color perceived by the normal human eye when stimulated by a wavelength of approximately 500–570 nm.
[0105] In some embodiments, the visualization agent is present in the hydrogel system while being applied into a cavity such as the uterus by the delivery system described herein. In such applications, the target tissue on the uterine surface is not visualized or cannot be visualized. The presence of the visualization agent during application may allow the user to detect when the cavity is sufficiently filled with material due to the presence of excess material leaving the target cavity. In the case of intrauterine applications after surgical intervention, the presence of a blue or green visualization aid allows for differentiation from excess bodily blood and fluids resulting from the surgery, as well as confirmation that application and hydrogel crosslinking have occurred.
[0106] Suitable biocompatible visualizers are FD&C BLUE #1 and FD&C BLUE #2 indocyanine green. Methylene blue, while offering suitable visualization potential, is less desirable due to its reported potential to cause allergies in gynecological procedures compared to other medically acceptable colorants and dyes that provide a contrasting color to the red serous blood-like fluid. One or both of these visualizers may be present in the final electrophilic-nucleophilic reactive precursor species mixture at concentrations greater than 0.05 mg / ml, and in some embodiments at least 0.1 to about 12 mg / ml, and in further embodiments in the range of 0.1 to 4.0 mg / ml, although higher concentrations up to the limit of the visualizer's solubility may be used. These concentration ranges have been found to impart the desired color to the hydrogel without interfering with the crosslinking time (measured by the time it takes for the reactive precursor species to gel) and have been determined to be more radioactively stable than other visualizers such as methylene blue. The visualizers may also be fluorescent molecules. The visualizers are generally not covalently bonded to the hydrogel. Those skilled in the art will recognize that additional ranges of visualization agent concentrations beyond those specified above are conceivable and fall within the scope of this disclosure.
[0107] In some embodiments, the method is used to form a hydrogel on tissue until the color of the hydrogel indicates that a predetermined volume of hydrogel has been deposited on or within the tissue. The precursor is continuously introduced into the space until a suitable volume is deemed to have been achieved by the color of the material entering and flowing out of the space, as indicated by observing a visualizer placed in the flowing material. For example, two fluid precursors associated with a blue dye are introduced into and delivered into the uterus until the color of the material leaving the uterus indicates that unwanted fluid has been flushed out of the uterus and the uterus is substantially full of precursors.
[0108] Drug delivery In many applications, the hydrogel applied in contact with the patient's tissue may contain a bioactive agent. Intrauterine drug delivery routes offer several potential advantages. Firstly, the uterine and vaginal linings are less prone to local irritation than the mucous membranes of the cheeks or eyes, due to their proximity to the depot. Secondly, intrauterine enzyme activity is significantly lower than that of the gastrointestinal route. Thirdly, intrauterine routes can avoid the metabolic losses due to first-pass administration seen in oral administration routes, improving the bioavailability of the drug and potentially reducing the required dose. Furthermore, the uterine cavity provides a cecum, which, unlike the gastrointestinal tract with its continuous flow, can be filled. Like any topical delivery device, intrauterine therapeutic targets generally benefit greatly from improved treatment with reduced systemic effects resulting from higher doses of traditional administration routes. The use of hydrogels formed in situ for drug delivery is described in U.S. Patent No. 9,125,807 to Sawhney, et al., "Adhesive Hydrogels for Ophthalmic Drug Delivery" (incorporated herein). Hydrogels can also be improved with respect to imaging, as described in U.S. Patent No. 8,383,161 to Campbell, et al., "Radiopaque Covalently Crosslinked Hydrogel Particle Implants" (incorporated herein).
[0109] Cross-linked hydrogel materials can conveniently be used for topical or systemic drug therapy by intrauterine administration. Bioactive agents or drug compounds that can be added and delivered from the cross-linked polymer or gel include: proteins, glycosaminoglycans, carbohydrates, nucleic acids, inorganic and organic bioactive compounds, where certain bioactive agents are not limited to: enzymes, anti-infective agents, antifungal agents, anti-inflammatory agents, antitumor agents, local anesthetics, hormones, angiogenic agents, angiogenic inhibitors, growth factors, antibodies, neurotransmitters, psychotropic agents, anticancer agents, chemotherapeutic agents, drugs affecting fertility, genes, oligonucleotides, or combinations thereof. In some embodiments, the type of treatment targets medical conditions relating solely to women's health; these may be local conditions within the uterus itself, and / or health conditions that can be treated by transmucosal transport into the systemic circulation within the uterus, such as hormone therapy for postmenopausal women.
[0110] To prepare such a crosslinked composition, the bioactive compounds described above may be mixed with any of the solutions used to prepare the hydrogel, and the drug may be added to the aqueous solution before preparing the aqueous solution or during the sterile production of the monomer. In further or alternative embodiments, the bioactive compounds may be added to the accelerator solution for incorporation into the hydrogel. When using the crosslinked composition for drug delivery as described above, the amounts of the crosslinkable polymer, crosslinking agent, and dosage agent introduced into the host may be selected depending on the specific drug and the condition being treated, in accordance with the fact that they do not significantly interfere with the properties of the hydrogel.
[0111] In some embodiments, one or more activators are present in the separation phase when the crosslinking agent and the crosslinkable polymer react to form a crosslinked hydrogel. This phase separation prevents bioactive substances from being involved in chemical crosslinking reactions, such as the reaction between ester groups and amine groups. The separation phase may also help to control the release kinetics of the activators from the crosslinked product or gel, where the “separation phase” may be an oil (oil-in-water emulsion), a biodegradable excipient, and the like. Biodegradable excipients that may contain an activator include encapsulating excipients, such as fine particles, microspheres, microbeads, and micropellets, where the activator is encapsulated in bioerodable or biodegradable polymers, such as poly(anhydride), poly(hydroxy acid), poly(lactone), poly(trimethylene carbonate), poly(glycolic acid), poly(lactic acid), poly(glycolic acid)-co-poly(glycolic acid), poly(orthocarbonate), poly(caprolactone), crosslinked biodegradable hydrogel network structures such as fibrin glue and fibrin sealant, caged and entrapping molecules such as cyclodextrin, and polymers and copolymers such as molecular sieves. Microspheres made from polymers and copolymers of poly(lactone) and poly(hydroxy acid) are particularly suitable as biodegradable encapsulating excipients. Drug delivery excipients may further include visualization agents.
[0112] These bioactive agents may include anti-infective or antifungal agents for the treatment of uterine infections, where the effectiveness of the bioactive agent is improved due to its proximity to its local target. For example, the following antimicrobial agents may be preferred: broad-spectrum antibiotics (e.g., penicillin and cephalosporins), metronidazole (for bacterial vaginosis and trichomoniasis), fluconazole (antifungal agent - for vaginal candidiasis (yeast infection)), doxycycline, or azithromycin. In some cases, it may be necessary to deploy anti-infective agents prophylactically during high-risk treatment or in high-risk immunocompromised populations. Anti-inflammatory agents, such as NSAIDs or steroids, are another type of agent that may be used to treat conditions such as endometriosis, without the systemic side effects associated with the long-term consumption of these agents. In other embodiments, the application of a hydrogel containing an antimicrobial or antiviral agent as an adjunct barrier to the susceptible cervix prevents premature birth due to infection.
[0113] Hormones and other active ingredients benefit from local intrauterine delivery, ranging from the treatment of endometriosis and contraception to hormone replacement therapy (HRT) in postmenopausal women. Oral contraceptive use is associated with an increased risk of thromboembolism and breast cancer. Less harmful side effects of oral contraceptive use, such as mood swings, weight gain, intermenstrual bleeding and petechiae, and decreased libido, can lead to inconsistent oral administration or discontinuation, resulting in a failure rate as high as 5% during the first year of oral contraceptive use. At another stage of the life cycle, oral HRT in postmenopausal women is associated with an increased risk of coronary heart disease, stroke, and venous thromboembolism, as well as an increased risk of breast cancer with longer treatment duration.
[0114] An intrauterine device (IUD) is a mechanical device that can deliver hormones slowly and directly to the uterus. Mirena (a commercially approved levonorgestrel-releasing IUD) is approved for delivery and effectiveness lasting up to 5 years. IUDs offer the advantage of long-term local delivery of progesterone or levonorgestrel through a reservoir integrated into the arm of the T-shaped device. While IUDs have been clinically demonstrated to have fewer side effects associated with lower systemic uptake of hormone therapy, they still carry risks of irregular bleeding, perforation, and bacterial / fungal colonization as a result of the mechanical nature and design of the device. See, for example, U.S. Patent Application Publication 2018 / 0008536 to Jukarainen et al., “Drug Delivery System Comprising a Non-Steroidal Anti-inflammatory (NSAID) and a Progestogenic Compound and Method for Manufacturing” (incorporated herein).
[0115] In one embodiment, application involves the delivery of an in-situ forming hydrogel having an excess of hormones ranging from 10, 20, 30 to over 50% suspended in a premixed hydrogel precursor component of an applicator system. Sustained hormone delivery is achieved by the low solubility of these drugs, enabling long-term direct delivery to the uterus for the treatment of conditions such as endometriosis. In HRT, higher hormone doses suitable for contraception or the treatment of endometriosis may have adverse side effects even when delivered directly to the uterine space. In other embodiments, where precise delivery control is required, low-sustaining levels of hormone therapy can be achieved by secondary encapsulation of the hormones and suspension of the encapsulated active ingredient in a premixed precursor component of an applicator system for delivery. In some embodiments, secondary encapsulation may use non-erosive materials to achieve delivery times for even longer treatments; these non-erosive particles are released when the hydrogel matrix is broken down and reabsorbed, and then released by normal excretion.
[0116] In other embodiments, the application of hydrogel to the uterine cavity utilizes the high-density angiogenesis of the uterus, primarily the uterine veins, to deliver the active ingredient systemically. Active ingredients delivered via the uterus avoid the first-pass effect, where the total oral bioavailability of the drug may be reduced due to absorption into the hepatic portal system and metabolism by the liver, leading to an overdose before achieving the therapeutic effect. For some active ingredients, oral delivery is not an option at all due to the complete loss of the drug in the first-pass effect. In other cases, oral administration results in side effects associated with repeated dosing.
[0117] Bisphosphonates, a type of drug used to treat osteoporosis, are associated with gastrointestinal disorders, inflammation, and esophageal erosion. In one embodiment, intrauterine application of a hydrogel containing bisphosphonate particles or suspensions of encapsulated bisphosphonates was associated with oral administration to provide a systemic therapeutic level using small amounts of the drug without side effects. In postmenopausal women, intrauterine drug reservoirs may be used to deliver the drug over extended periods of several months.
[0118] Selected Embodiment - Prevention of Uterine Cavity Adhesion In some embodiments, the method includes preventing adhesions within the uterus, and the method includes introducing a fluid material into the uterus to tamponade the surface of the uterus. Tamponade may be effective in reducing bleeding. The material may be a hydrogel. The material may be a stent. The material may separate at least two opposing portions of its surface to prevent contact between the two opposing portions. The material may substantially fill the uterus. The material may be delivered by a flexible catheter with a rounded, non-traumatic tip. The material may be delivered by a catheter delivery system in conjunction with features outside the catheter shaft, such as an outflow limiter, to reduce material runoff and reduce variability in material application. The material may be delivered by transcervical delivery or laparoscopy. The catheter may have a small profile and diameter, ideally less than 5.5F, to reduce the exit trajectory profile after substantially filling the uterus. The resulting application can be visualized under ultrasound during and after administration, allowing for quantification of tissue separation and potentially leading to improved adhesion prevention.
[0119] The material may be substantially formed within the uterus. The material may contain a visualization agent, such as a blue or green colorant. The material may be partially formed outside the uterus, and the formation of the hydrogel may be completed within the uterus.
[0120] The desired intrauterine anti-adhesion device delivers a hydrogel composition that is easy to use, locally persists throughout the primary phase of adhesion, and is reabsorbable and biocompatible without interfering with normal tissue repair processes. See Torres-De La Roche LA, Campo R, Devassy R, et al. Adhesions and Anti-Adhesion Systems Highlights. Facts Views Vis Obgyn. 2019;11:137-149 (incorporated herein). The desired system may persist long enough to meet the healing time window (3-10 days), but not long enough for the adhesion barrier itself to be encapsulated as part of the healing response. When preventing intrauterine adhesions, accidental contact during the procedure or tissue damage resulting from the procedure itself can lead to loss of basement membrane structure, blood-material interactions, provisional matrix formation, cell necrosis, and inflammatory responses. These events can similarly affect the degree or extent of granulation tissue formation, foreign body reaction, and the development of fibrosis or fibrous capsule. In implants, the organizing process due to fibrous tissue development leads to the well-known fibrous capsule formation at the tissue / material interface. The ideal persistence of a reabsorbable adhesion barrier material is 2:1: The material needs to persist for a considerable time to provide a suitable barrier for adhesion formation, but not long enough for adhesion to form due to the fibrous covering of the barrier material itself. [Examples]
[0121] Examples Example 1: Tabletop polymer test of premixed formulations This example demonstrates the effect of solids content percentage and precursor composition on the decomposition of the hydrogel formulation.
[0122] A set of hydrogels was formed by crosslinking electrophilic and nucleophilic precursors, identified as precursor A and precursor B, respectively. Sample 1 in Table 1 was a control sample prepared according to a previous study described in U.S. Patent No. 7,347,850. Precursor A was dissolved in a 0.01 M monobasic sodium phosphate buffer solution (pH 4.0). Precursor B was separately dissolved in a 0.1 M sodium borate buffer solution (pH 9.5) to form an amine precursor / accelerator solution. As shown in Table 1, the delivery modes of the precursors in Sample 1 were separated (S). A 1.5 ml aliquot of precursor A solution was drawn into the first syringe. A 1.5 ml aliquot of precursor B solution was drawn into the second syringe. A Y-connector with two Luer lock connectors was attached to a 1 / 4-inch tube adapter to a Luer lock fixture, and the tube adapter was attached to a 1 / 4-inch ID clear silicone tube (Silastic®) containing a static mixing element proximal to the Y-connector. A first syringe and a second syringe were attached to the Y-connector, and plunger caps were attached to the ends of the syringes to ensure equidistribution from both syringes. The syringes were deployed and material having the solids percentage according to Table 1 was injected into the length portion of the silicone tube. Initial gelation was observed to occur within approximately 0.5–5 seconds, as evidenced by the movement of air bubbles within the tube.
[0123] In samples 2-14 of Table 1, precursors A and B were premixed with an acid buffer (PM), and then mixed with a basic accelerator solution to form a hydrogel. For each premixed sample, the ester-amine precursor solution was prepared by mixing precursors A and B in a 1:1 ratio, with the reactive ester terminal group of precursor A to the reactive amine terminal group of precursor B, and dissolving the mixture in a 0.1% NaH2PO4 (monobasic sodium phosphate) buffer solution (pH 4) to form the premixed ester-amine precursor solution. A 1.5 ml aliquot of the ester-amine precursor solution was drawn into the first syringe. The accelerator solution (pH approximately 9.8-9.9) was prepared by mixing 0.045 M sodium borate decahydrate with 0.2 M dibasic sodium phosphate. A 1.5 ml aliquot of the accelerator solution was drawn into the second syringe. The procedure described above was followed by the use of these two pre-filled syringes. Initial gelation was observed to occur within 3–5 seconds, as evidenced by the movement of air bubbles within the tubes.
[0124] The samples were able to remain gelled for 5 minutes to ensure complete curing. Using a razor blade, the silicone tubes containing each gel were cut into three equal length sections, and two gel samples (approximately 0.2 g) were taken from each length section. The gel samples were placed in physiologically representative phosphate-buffered saline (PBS) under 50°C (accelerated) and 37°C (real-time) conditions and subsequently checked periodically until they were no longer visually detectable. The range of disappearance times for each set of three gel samples at 50°C and 37°C is shown in Table 1.
[0125] [Table 1]
[0126] In samples 1-3, 6, and 7, precursor A was a 4-armed PEG-based precursor (4A20k PEG SG) with a molecular weight of 20,000 Da and succinimidyl glutarate (SG) functional terminal groups. Precursor B was trilysine acetate. Solids content varied from 4 to 9 percent. Elimination times at 37C ranged from 20 to 41 days, and generally decreased as solids content decreased.
[0127] In samples 4, 5, and 8-10, precursor A was a 4-armed PEG-based precursor (4A40k PEG SG) with a molecular weight of 40,000 Da and succinimidyl glutarate (SG) functional end groups. Precursor B was an 8-armed PEG-based precursor (8A20k PEG NH2) with a molecular weight of 20,000 Da and primary amine functional end groups. The solids content varied from 4% to 7.5%. The elimination time at 37C ranged from 16 to 31 days, with samples with lower solids content having shorter elimination times.
[0128] In samples 11-14, precursor A was an 8-armed PEG-based precursor (8A15k PEG SS) with a molecular weight of 15,000 Da and succinimidyl succinate (SS) functional end groups. Precursor B was trilysine acetate in all samples. The solids content varied from 7.5% to 12%. The elimination time at 37C ranged from approximately 5 days (113 hours) to approximately 8 days, with samples with lower solids content having shorter elimination times.
[0129] Additional gelation time studies were conducted using the premixed precursor described in this example. In one study, 0.1 ml of the premixed ester-amine precursor solution was pipetted into a test tube containing a flea stirring bar. The test tube was positioned in the center of a heated stirring plate and set to 1000 rpm. 0.1 ml of an aliquot of the accelerator solution was added to the test tube using a pipettor. Gelation time was known as the time from the time of injection to the time when the moving stirring bar was stopped. The injectability of the formulation through a catheter was also tested to determine whether there was evidence of catheter blockage and whether there was the ability to pause delivery. Gelation times of approximately 2.5–2.9 seconds were observed for the accelerator solution at pH 10.03. Gelation times of 1.5–1.8 seconds were observed for the accelerator solution at pH 10.3. A blend of the accelerator solution with pH 10.03 was delivered by both continuous and intermittent infusion (with a 1-second pause) without catheter clogging. Using the accelerator solution with pH 10.3, a gelation time as short as 1.5 seconds was observed during continuous delivery without catheter clogging. The results indicated that increasing the pH of the accelerator solution shortened the gelation time, and that intermittent delivery was made possible by the hydrogel formulation.
[0130] This study demonstrated that premixing of ester and amine precursors can produce hydrogels with desired ranges of disappearance and gelation times. The disappearance time was shown to be influenced by the solids content percentage, ester functional groups, and the molecular weight and composition of each precursor. The disappearance times of the separated formulations were outside the target range of approximately 3–29 days for intrauterine use. Disappearance times within the target range were observed for most premixed formulations.
[0131] Example 2: Swelling study This example demonstrates the preparation of a hydrogel using a premixed precursor solution and an accelerator. The swelling of the hydrogel is shown depending on the concentration of the premixed precursor solution and the pot life of the premixed precursor solution.
[0132] Two premixed precursor solutions were prepared. A 20% solids precursor solution was prepared by dissolving 1 g of 8-arm 15,000 Da PEG succinimidyl succinate (SS) and 1:1 functional group equivalents of trilysine acetate (approximately 27 mg) in 5 ml of 20 mM pH 4 NaH 2PO 4 (monobasic diphosphate) buffer solution. A 24% solids precursor solution was prepared by dissolving 1 g of 8-arm 15,000 Da PEG succinimidyl succinate (SS) and 1:1 functional group equivalents of trilysine acetate (approximately 27 mg) in 4.2 ml of pH 4 NaH 2PO 4 (monobasic diphosphate) buffer solution.
[0133] After a predetermined period ("pot life"), 1.5 ml of a 20% solids precursor solution was drawn into the first syringe. 1.5 ml of a pH 9.9 sodium borate / dibasic sodium phosphate accelerator solution, prepared by mixing 0.045 M sodium borate decahydrate with 0.2 M dibasic sodium phosphate, was drawn into the second syringe. A Y-connector with two Luer lock connectors was attached to a 1 / 4-inch tube adapter to a Luer lock fitting, and the tube adapter was attached to a 1 / 4-inch ID clear silicone tube (Silastic®) containing a static mixing element, located proximal to the Y-connector. The first and second syringes were attached to the Y-connector, and plunger caps were fitted to the ends of the syringes to ensure equal volume deployment from both syringes. The syringes were deployed, and the material was injected into the length portion of the silicone tube. Initial gelation was observed to occur within 3–5 seconds, as evidenced by the movement of air bubbles within the tube. The sample was able to continue gelling for up to 5 minutes. A gel with a "10% solids content" was formed based on the precursor concentration. In another sample, the procedure described above was modified by first drawing a 24% solids content precursor solution into the first syringe, and a gel with a "12% solids content" was formed.
[0134] Using a razor blade, each silicone tube containing a gel was cut into three equal length sections, and a gel sample (approximately 0.2 g) was taken out from each length section. The gel samples were weighed to provide an initial "Weight In" and then placed in physiologically similar phosphate-buffered saline (PBS) at 37°C. After 24 hours, the samples were carefully removed, blotted dry to remove excess fluid, and weighed again to provide a "Weight Out". Swelling was determined by the following formula:
number
[0135] Hydrogel samples were prepared with three pot-life times: 5 minutes, 30 minutes, and 60 minutes. Figure 11 shows a plot of swelling of each hydrogel according to the pot-life in minutes. Percent swelling was observed to increase with increasing solid percentage of the premixed precursor solution. Hydrogel swelling also increased with pot-life time. The 24-hour swelling of the hydrogels was in the range of approximately 21 wt% to approximately 46 wt%.
[0136] Example 3: Tabletop Polymer Modulus Test This example investigated the effects of the precursor composition and premixing on the modulus of the hydrogel over time.
[0137] A set of hydrogels was formed by crosslinking an electrophilic precursor and a nucleophilic precursor, identified as precursor A and precursor B, respectively. Four precursor formulations were studied, as shown in Table 2. Formulations 1-3 were used to prepare the hydrogels by premixing precursor A and precursor B in an acidic buffer. Formulation 4 is a comparative formulation in which the hydrogel was formed by separate solutions of precursor A and precursor B.
[0138] In preparations 1-3, the ester-amine precursor solutions were prepared by mixing precursor A and precursor B in a 1:1 equimolar ratio (reactive ester terminal group of precursor A versus reactive amine terminal group of precursor B) according to Table 2, and dissolving the mixture in a 0.1% NaH2PO4 (monobasic sodium phosphate) buffer solution (pH 4). 1.5 ml aliquots of the ester-amine precursor solution were drawn into the first syringe. The accelerator solution (pH approximately 9.8-9.9) was prepared by mixing sodium borate decahydrate and dibasic sodium phosphate according to the weight percentages shown in Table 2. 1.5 ml aliquots of the accelerator solution were drawn into the second syringe. A Y-connector with two Luer-lock connectors was attached to a 1 / 4-inch tube adapter to a Luer-lock fixture, and the tube adapter was attached to a 1 / 4-inch ID clear silicone tube (Silastic®) containing a static mixing element, located proximal to the Y-connector. A first syringe and a second syringe were attached to the Y-connector, and plunger caps were attached to the ends of the syringes to ensure equivolume dispensing from both syringes. The syringes were dispensed, and the material was injected into the length portion of the silicone tube. Initial gelation was observed to occur within 3–5 seconds, as evidenced by the movement of bubbles within the tube. The sample was allowed to continue gelling for a period of time, which was more than 20 times the initial gelation time (over 2.5 minutes), to ensure complete curing.
[0139] Regarding formulation 4, precursor A (4a20k PEG SG) was dissolved in 0.1% monobasic sodium phosphate buffer solution, pH 4, to form an ester precursor solution. 1.5 ml of the ester precursor solution was drawn into the first syringe. Separately, precursor B (trilysine acetate, abbreviated as TLA) was dissolved in 1.2% sodium borate decahydrate buffer solution, pH 10.3, to form an amine precursor / accelerator solution. 1.5 ml of the amine precursor / accelerator solution was drawn into the second syringe. The above procedure was followed using these two pre-filled syringes.
[0140] Preparations 3 and 4 had similar compositional components, but the hydrogel samples were prepared by mixing the components differently. Preparation 3 was used to prepare a premixed precursor composition having an acidic pH (pH 4), which was reacted with a basicity accelerator solution (pH 9.9). Preparation 4 was used to prepare an acidic ester precursor solution (pH 4) and a basic amine solution (pH 10.3), which were then mixed. Therefore, the comparison of preparations 3 and 4 shows the effect of premixing versus not premixing the precursor. The comparison also shows the effect of higher salt concentrations required to achieve the pH 10.3 basic amine solution necessary to allow the ester and amine to crosslink immediately upon mixing.
[0141] [Table 2]
[0142] Using a razor blade, each silicone tube containing a gel was cut into three equal length sections, and a gel sample (approximately 0.2 g) was taken from each length section. The gel samples were placed in simulated uterine fluid (SUF) with a selected volume matching the target dilution ratio. The term dilution ratio is the ratio of the mass of the SUF to the mass of the gel sample. The dilution ratio was modified to simulate different constrained volume scenarios. For example, testing the disappearance of a 0.2 g gel sample in 50 g of SUF provides a dilution ratio of 250:1 (50 g SUF: 0.2 g gel). The disappearance of the formed gel was tested at dilution ratios of 5:1, 25:1, 50:1, and 250:1. Lower dilution ratios were used as a means of shaping the constrained volume in vivo location to determine whether different diffusion rates of buffer salts from the gel or different reactions to total buffering were observed. It is hypothesized that gel samples disappear more rapidly in lower dilution media due to reduced diffusion of buffer salts from the gel and a resulting longer period of high pH. Higher pH is thought to cause more rapid hydrolysis of ester functional groups involved in crosslinking with amine functional groups, leading to earlier degradation and earlier visual disappearance of the gel sample. The components of SUF are shown in Table 3 in comparison with phosphate-buffered saline (PBS). The pH of SUF at 50C was measured to be 7.24. The pH of PBS at 50C was measured to be 7.57.
[0143] [Table 3]
[0144] The modulus of each gel sample was measured over time at 50°C and 37°C (real-time) conditions at various SUF dilutions. The modulus could be measured in the range of 5 kPa to 200 kPa. The gel samples were also periodically checked until they were no longer visually detectable. Each gel sample was also tested in PBS at a 250:1 dilution.
[0145] Figures 12–15 show the modulus at 37C, with respect to time and dilution, for gel samples prepared from formulations 1–4. Note that the time axis is not linear. Each gel sample showed an initial rapid decrease in modulus over a period of approximately two days. The initial rate of decrease in modulus and the percentage decrease in modulus differed depending on the dilution. The time to reach the lower limit modulus (5 kPa) also depended on the dilution. Generally, a decrease in dilution correlated with a lower modulus at a given time point.
[0146] For comparison, the formulation (Formulation 4, Figure 15) showed a rapid decrease in modulus in the gel sample at a 5:1 dilution ratio. The modulus decreased from 70 kPa at the time of gel formation to virtually zero after approximately 2 days. In contrast, the premixed formulations at a 5:1 dilution ratio showed an initial decrease of approximately 2 days, followed by one or more extended regions of more gradual modulus decline. Formulations 1 and 3 reached virtually zero modulus after approximately 5 days. Formulation 2 showed a modulus of over approximately 10 kPa after 41 days. These results indicate that the modulus profile depends on the ester precursor and solids percentage of the premixed formulation.
[0147] A comparison of Figures 14 and 15 (corresponding to formulations 3 and 4) demonstrates that premixing of precursors can result in hydrogels with significantly different modulus properties. Hydrogels formed from premixed precursors (formulation 3) reached virtually zero modulus at a 5:1 dilution ratio in approximately 5 days, compared to 2 days for formulation 4, extending the period by approximately 250%. At each dilution ratio, gel samples from premixed precursors maintained their modulus for a particularly longer period than gel samples from separated precursors. This result suggests that accelerated hydrolysis (or "autohydrolysis") occurred in gel samples from separated precursors (formulation 4) due to the higher pH required to initiate the crosslinking reaction, and that this problem was mitigated by premixed delivery of the precursors (formulation 3). Avoiding autohydrolysis results in hydrogels that are sufficiently rigid to resist removal from the uterus for a longer period.
[0148] Figure 16 shows a plot of the percentage modulus loss per unit time for each formulation, from top to bottom, corresponding to the dilution ratio of gel samples from formulation 2, formulation 3, formulation 1, and formulation 4. The modulus loss rate for gels from premixed formulations 1-3 was less sensitive to the decrease in dilution ratio from 250:1 to 50:1 than that for gels from formulation 4.
[0149] Figure 17 shows a comparison of the modulus over time for gel samples from formulations 3 and 4 at a dilution ratio of 250:1. The bar graph shows the absolute modulus of each gel over time in kPa, while the curve shows the percentage modulus of each gel over time. Data were collected at 50C to accelerate the experiment, and the times shown were adjusted for the acceleration of correlation against 37C. The initial modulus of the gel sample from formulation 3 was 91 kPa, which decreased linearly to 56 kPa (i.e., 62% of the original modulus) over 2.1 days. The initial modulus of the gel sample from formulation 4 was 70 kPa, which decreased linearly to 30.5 kPa (i.e., 44% of the original modulus) over 2.1 days. The rate of decrease in modulus was 18% per day for the premixed formulation, compared to 27% per day for the separated formulation. Therefore, the premixed formulation showed a higher initial modulus and a more rapid initial decline in modulus compared to the separated formulation. Over longer periods, the decline in modulus for the separated formulation was more pronounced overall than that for the premixed formulation. At modulus levels of approximately 5–10 kPa, tubular gel samples were observed to lose the mechanical strength necessary to remain immobile. Hydrogels placed in utero are expected to be prone to being removed once their modulus drops to approximately 1–10 kPa, with their persistence in utero decreasing along with the decline in modulus. The premixed formulation maintained a modulus above 10 kPa for approximately 23 days, while the separated formulation declined to below 10 kPa at approximately 14 days and remained in the range of approximately 1–10 kPa for 14–17 days. Table 4 summarizes the time to modulus below 10 kPa and the time to complete visual disappearance of the gel for the four dilution ratios used. At each dilution level, the premixed formulation maintained the threshold modulus for a longer period. However, the number of days until gel disappearance was shorter for the premixed formulation than for the separated formulation at each dilution level. In all cases, the modulus threshold was reached before the complete disappearance of the gel. It was also observed that the interval between the time until the modulus became <10 kPa and visual disappearance increased with increasing dilution levels.The pH of the preparation is assumed to cause the separated preparation to reach modulus loss earlier.
[0150] [Table 4]
[0151] The results show a higher initial modulus and improved modulus retention for the premixed formulation compared to the separated formulation. The results also show that the constrained volume affects the gel's persistence and modulus over time. The results suggest that the premixed formulation is more suitable than the separated formulation for privileged applications, such as uterine use, because intrauterine persistence was shown to correlate with a gel having sufficient rigidity to resist expulsion from the uterus. The intrauterine persistence of the placed hydrogel formulation is expected to correlate with the time until the modulus falls below approximately 10 kPa at dilution ratios of approximately 50:1 to 250:1. This characteristic of intrauterine persistence was further investigated in vivo in Examples 7 and 8.
[0152] Example 4: Swelling test in simulated uterine fluid This example studied the swelling of the premixed formulation from Example 3.
[0153] Gel samples were prepared according to Example 3 using Formulation 3. Gel swelling followed the method of Example 2, except that SUF medium at a dilution ratio of 250:1 was used instead of PBS. Table 5 shows the raw and calculated results.
[0154] [Table 5]
[0155] The results show that this premixed formulation swelled by approximately 64% to 77% after 24 hours. For comparison, the typical swelling of the gel formed from separated formulation 4 in Example 3 was approximately 110% to 120% after 24 hours.
[0156] Example 5: Tabletop model filling test This example demonstrates the effect of the solids content percentage of the hydrogel system on the filling performance.
[0157] A pair of uterine filling models were prepared from a double layer of thermoformed plastic sheets along the sides of a triangle to form a closed triangular cavity with a base of approximately 7 cm and a height of approximately 10 cm. The vertices of the triangular cavity were cut out to provide an opening to the cavity. Saline solution was provided in the cavity to mimic residual fluid in the uterus. Two hydrogel precursor samples were tested: formulation 4 of Example 3 (Sample 1), and formulation 4 of Example 3 (Sample 2) diluted 50% with saline solution. When prepared, the solids percentage of hydrogel precursor sample 2 was approximately 4.4%. The solids percentage of sample 1 was approximately 8.7%, as shown in Table 2. The saline solution was colorless, but the hydrogel precursor samples were blue when delivered.
[0158] Using an applicator as shown in Figure 1, catheter 108 was inserted into the lumen opening until the flow limiter 106 was firmly pressed against the lumen opening. A syringe was prepared according to Example 3. Each sample was injected into the lumen, while keeping the flow limiter 106 firmly pressed against the lumen opening. When hydrogel precursor sample 2 was placed in the lumen, most of the hydrogel leaked out as a viscous liquid through the flow limiter 106, resulting in the lumen being only partially filled with a soft, viscous hydrogel. Sample 1 demonstrated effective placement of the hydrogel. The gel was observed to push out the (colorless) residual liquid during the filling process. With the lower solids sample (Sample 2), the results indicated that the residual fluid in the lumen caused dilution, thereby preventing the formation of a persistent solid hydrogel in the lumen. However, with the higher solids sample, the hydrogel was observed to be more dilution-resistant and was able to expel the residual fluid during the filling process. Additional studies were conducted by changing the amount of headspace in the syringe. An increase in headspace was observed to create a hydrogel in which microbubbles were trapped. This result suggests that the contrast of the hydrogel when imaged by ultrasound was partly due to the presence of microbubbles within the hydrogel.
[0159] This example demonstrates that the solid percentage of a hydrogel precursor formulation affects dilution resistance due to residual fluid and overall packing performance. The results show that the hydrogel system had a lower limit to the range of solid percentages required to form a persistent solid hydrogel in the uterus compared to a given hydrogel system.
[0160] Example 6: Exvivo uterine tabletop study This example illustrates the use of a hydrogel system for delivering hydrogel into an excised human uterus.
[0161] In this example, a human uterus was obtained after hysterectomy according to a standard medical research protocol. The weight of the ex vivo uterus was 101 grams.
[0162] The delivery system was assembled according to the diagram in Figure 1. The volume of each syringe was 10 ml. The ester-amine precursor solution was prepared by mixing 8a15K PEG SS and trilysine acetate in a 1:1 ratio of reactive amine to reactive ester terminal group, and dissolving the mixture in a 20 mM monobasic sodium phosphate buffer solution (pH 4). 5 ml aliquots of the ester-amine precursor solution were drawn into the first syringe. 5 ml of pH 9.9 sodium borate / dibasic sodium phosphate accelerator solution was drawn into the second syringe. In both cases, the first solution was colored with diluted FD&C blue #1. The second solution was not colored.
[0163] A uterine eliminator (Integra LifeScience, product number 30-6000) was used to determine the depth of the uterine fundus for ExVivo. The uterine eliminator was then positioned along the assembly of catheter 108 and outflow limiter 106. The position of the outflow limiter's cap element was adjusted along the catheter, using the uterine eliminator as a guide, to ensure a gap of approximately 1 cm between the distal end of the installation tip 102 and the base during hydrogel placement. The catheter and outflow limiter were connected to the Y-connector and syringe assembly via a Luer connector. The catheter was inserted into the uterus until the distal portion of the cap element entered the cervical canal and the proximal portion of the cap element was pressed against the cervical opening. Forceps were used to grasp the cervical lips to provide resistance during the insertion process. The system was held by the syringe holder 118 and strong pressure was applied between the cervix and the cap element while the plunger was pushed to fully deploy the hydrogel system from the syringe. Next, the catheter was withdrawn from the uterus, leaving the outflow limiter in contact with the cervical opening. After approximately 2 seconds, the outflow limiter was grasped by the support sheath 103, and the cap element 109 was pulled away from the cervix. The uterus was weighed again. The increase in the weight of the uterus after the placement of the placed hydrogel was 10 grams. The majority of the hydrogel precursor remained in the uterus after delivery, with a relatively small amount of precursor forming a gel surface coating on the cervical opening. There was no evidence that the placed hydrogel was expelled from the uterus.
[0164] Immediately afterward, the uterus was cut along the sagittal plane. A continuous hydrogel was observed that completely filled the uterine cavity, including the cervix. The solid hydrogel was removed, and it was found that it retained its shape after removal. The uterus was further evaluated by cutting into the fallopian tube to confirm the presence of hydrogel. No hydrogel was found in the fallopian tube. The results of this study indicate that the hydrogel system is effective in delivering hydrogel to the human uterus to form a hydrogel that fully fills the uterine cavity, as well as being firm enough to separate and tamponade the uterine wall and not be discharged at the end of the placement procedure. Furthermore, the hydrogel did not enter the fallopian tube.
[0165] Example 7: Study on perihysterectomy in humans This example illustrates the use of a hydrogel system for delivering hydrogels into a human uterus in situ.
[0166] Six human patients were part of this study. For each patient, a modified Cook® Goldstein Sonohysterography Catheter was used. The Cook Goldstein Sonohysterography Catheter has a movable, acorn-shaped positioner that can be positioned along the catheter, with an ink band placed on the catheter as a reference mark. The catheter was connected via a Luer lock to a dual syringe assembly as described below. In this study, the Cook Goldstein Sonohysterography Catheter was modified by cutting the catheter at the proximal locations of both the rounded closed tip and the oval side port. As modified, the catheter had an open port at the distal tip.
[0167] Patient selection was based, firstly, on the determination that a hysterectomy was medically necessary for the patient, and secondly, on the patient's willingness to participate in the experimental study. Prior to enrollment in the study, participants underwent diagnostic hysteroscopy and ultrasound examinations to ensure that there were no lesions that would make them ineligible for the study, and these were videotaped to assess endometrial thickness, cervical length, length and width of the uterine cavity, and both orifices.
[0168] For each patient, the first syringe was filled with the first solution, which contained a mixture of 18% (w / v) 8a15K PEG SS precursor and a certain amount of trilysine acetate precursor in a 20 mM monobasic sodium phosphate buffer solution (pH 4) to provide ester-terminated and amine-terminated groups in a 1:1 ratio. The second syringe was filled with a sodium borate / dibasic sodium phosphate accelerator solution, pH 9.8. The first precursor solution contained a diluted concentration of methylene blue. The second precursor solution was uncolored. The syringes were attached to a Y-connector for mixing by Luer lock connectors. Plunger caps were fitted to the ends of the syringes to ensure equal deployment of the two syringes. The Y-connector was connected to a 21-gauge tube adapter by a third Luer lock connector. The tube adapter was attached to a 21-gauge catheter made of clear polyethylene tubing. The acorn-shaped body was adjusted along the length of the catheter based on each patient's anatomical structure so that the tip of the catheter would be positioned at a selected location within the uterine cavity during the insertion step.
[0169] Following hysteroscopy and ultrasound, a modified Cook-Goldstein sonohysterography catheter was used to deliver the hydrogel system into the uterus. The delivery system catheter was inserted through the vagina into the cervix until resistance and visible catheter length indicated that the acorn-shaped body was positioned in contact with the cervical opening. Once positioned, the plunger cap was pressed to inject 10 ml of fluid from the syringe into the catheter and then into the uterine cavity. One finger of the surgeon was used to control the acorn-shaped body. The amount of force applied to the acorn-shaped body by the surgeon was used to adjust the amount of fluid released from the cervix during placement. After injection, the catheter with the acorn-shaped body attached was removed from the patient. After pressing the acorn-shaped body by hand for a few seconds, it was removed from the patient using ring forceps. Throughout the entire procedure, it was observed that the catheter tip did not become clogged during delivery.
[0170] Next, a hysterectomy was performed using surgical techniques to remove the entire intact uterus, as per standard treatment. No hydrogel discharge occurred during the hysterectomy. The removed uterus was incised and evaluated for the presence and distribution of hydrogel implants. All perihysterectomies demonstrated well-formed hydrogel implants. In each patient, intrauterine implant coverage was observed to be complete within the uterine body, and no gel was found in the fallopian tubes. Figure 18 shows a series of lesion photographs from one patient: upper left, removed uterus; upper right and lower left, removed uterus, cut and opened to show the placed hydrogel; lower right, cut and opened uterus with the removed implant. It can be seen that the gel coated the uterine cavity, and the removed implant is a continuous solid hydrogel with the shape of the uterine cavity. The thickness of the removed hydrogel implant was approximately 1 cm.
[0171] The results of this study demonstrate that a hydrogel system can fill the uterus in vivo with a persistent hydrogel. The results show that the hydrogel gelled within seconds and formed a hydrogel that filled the uterus and cervix, even in the presence of normal fluids within the uterus.
[0172] Example 8: In vivo sustained-effect study This example illustrates the use of a hydrogel system for delivering a sustained-release hydrogel into the human uterus in vivo.
[0173] In this feasibility study, ten female patients were selected. Patient selection was based, firstly, on the determination that endometrial ablation was medically necessary for the patients, and secondly, on the patients' willingness to participate in the experimental study. Prior to enrollment in the study, participants underwent diagnostic hysteroscopy and ultrasound examinations to ensure that there were no lesions that would make them ineligible for the study, and these were videotaped to assess endometrial thickness, cervical length, uterine cavity length and width, and both orifices.
[0174] The procedure was the same as outlined in Example 6, with the modification that each patient's uterus remained in situ.
[0175] Immediately after the placement of the hydrogel, a second ultrasound examination of the uterus was performed. Figure 19 shows ultrasound images of one patient before the ablation procedure (left image) and after the placement of the hydrogel (right image). In Figure 19, the location of the uterine cavity is indicated by arrows. It can be seen that the previously empty uterine cavity was filled by the hydrogel implant.
[0176] For each patient, the intrauterine implant coverage was determined to be complete, with no gel observed in the fallopian tube.
[0177] The cited technical papers (to the extent indicated below, as incorporated in this specification) 1.Di Spiezio Sardo,A.,Calagna,G.,Scognamiglio,M.,O’Donovan,P.,Campo,R.,&De Wilde,R.L.(2016).Prevention of intrauterine post-surgical adhesions in hysteroscopy.A systematic review.European Journal of Obstetrics and Gynecology and Reproductive Biology,203, 182-192.https: / / doi.org / 10.1016 / j.ejogrb.2016.05.050. 2.Hesham Al-Inany.Intrauterine adhesions.An update.Acta Obstet Gynecol Scand 2001;80:986-993. 3.Schenker,J.G.(1996).Etiology of and therapeutic approach to synechia uteri.European Journal of Obstetrics and Gynecology and Reproductive Biology,65(1),109-113.https: / / doi.org / 10.1016 / 0028-2243(95)02315-J. 4.Gomel,V.et al.:Pathophysiology of Adhesion Formation and Strategies for Prevention.J.Repro.Med.41:1,1996 5.Acunzo,G.,et al.(2003).Effectiveness of auto-cross-linked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic adhesiolysis:A prospective,randomized,controlled study.Human Reproduction,18(9),1918-1921.https: / / doi.org / 10.1093 / humrep / deg368 6.Guida,M.,et al.(2004).Effectiveness of auto-crosslinked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic surgery:A prospective,randomized,controlled study.Human Reproduction,19(6),1461-1464.https: / / doi.org / 10.1093 / humrep / deh238. 7.Johns DA,et al.,Initial feasibility study of a sprayable hydrogel adhesion barrier system in patients undergoing laparoscopic ovarian surgery. J Am Assoc Gynecol Laparosc 10 (3):334-338,2003. 8.Taskin,O.,et al.,(2000).Role of endometrial suppression on the frequency of intrauterine adhesions after resectoscopic surgery.Journal of the American Association of Gynecologic Laparoscopists,7(3),351-354.https: / / doi.org / 10.1016 / S1074-3804(05)60478-1. 9.diZerega,G.S.:Use of Adhesion Prevention Barriers in Ovarian Surgery, Tubalplasty,Ectopic Pregnancy,Endometriosis,Adhesiolysis,and Myomectomy. Curr.Opin.Obstet.Gynechol.8:3,1996. 10.Drug Facts and Comparisons.Facts and Comparisons,Publishers,St.Louis MO 1996. 11.Taskin,O.,Sadik,S.,Onoglu,A.,Gokdeniz,R.,Erturan,E.,Burak,F.,&Wheeler,J.M.(2000).Role of endometrial suppression on the frequency of intrauterine adhesions after resectoscopic surgery.Journal of the American Association of Gynecologic Laparoscopists,7(3),351-354.https: / / doi.org / 10.1016 / S1074-3804(05)60478-1. 12.Al-Inany,H.(2001).Intrauterine adhesions:An update.Acta Obstetricia et Gynecologica Scandinavica, 80(11),986-993.https: / / doi.org / 10.1034 / j.1600-0412.2001.801103.x. 13.Diamond,M.P.,Daniell,J.F.,Feste,J.,Surrey,M.W.,McLaughlin,D.S.,Friedman,S.,…Martin,D.C.(1987).Adhesion reformation and de novo adhesion formation after reproductive pelvic surgery.Fertility and Sterility,47(5),864-866.https: / / doi.org / 10.1016 / S0015-0282(16)59181-X. 14.Raziel A.,Arieli Sholmo:Investigation of the uterine cavity in recurrent aborters.Fertil Steril 1994;62:5,1080-1082. 15.Schenker,J.G.,&Margalioth,E.J.(1982).Intrauterine adhesions:an updated appraisal.Fertility and Sterility,37(5),593-610.https: / / doi.org / 10.1016 / s0015-0282(16)46268-0 15.March CM.Update:Intrauterine adhesions.Fertil News 1996;Vol.XVIV,No.1.Forum 16.Taylor,P.J.,Cumming,D.C.,&Hill,P.J.(1981).Significance of intrauterine adhesions detected hysteroscopically in eumenorrheic infertile women and role of antecedent curettage in their formation.American Journal of Obstetrics and Gynecology,139(3),239-242.https: / / doi.org / 10.1016 / 0002-9378(81)90001-6. 17.Nappi,C.,Di Spiezio Sardo,A.,Greco,E.,Guida,M.,Bettocchi,S.,&Bifulco,G.(2007).Prevention of adhesions in gynaecological endoscopy. Human Reproduction Update,13(4),379-394.https: / / doi.org / 10.1093 / humupd / dml061. 18.Nappi,C.,Di Spiezio Sardo,A.,Greco,E.,Guida,M.,Bettocchi,S.,&Bifulco,G.(2007).Prevention of adhesions in gynaecological endoscopy.Human Reproduction Update,13(4),379-394.https: / / doi.org / 10.1093 / humupd / dml061. 19.Piredda,A.,Marconi,D.,Exacoustos,C.,Sorrenti,G.,Zumpano,A.,Szabolcs,B.,…Zupi,E.(2003).Initial Feasibility Study of an Hydrogel Adhesion Barrier System in Patients Treated by Operative Hysteroscopy for Intrauterine Benign Pathologies.32°Annual Meeting of the AAGL,Las Vegas,Novembre 19-22,2003,10(3),25-26. 20.Victory,R.,Berman,J.,Diamond,M.,Kruger,M.,&Mcneeley,S.(2004).Evaluate the Safety and Efficacy of FlowFil Preventing Postoperative Uterine Bleeding and ThermaChoice Endometrial Ablation:33°Annual Meeting of the AAGL,San Francisco,Novembre 10-13,2004,11(3),29-30.
[0178] The embodiments described herein are for illustrative purposes only and are not intended to limit the scope. Additional embodiments are within the scope of the claims. Furthermore, although the present invention has been described with reference to specific embodiments, those skilled in the art will recognize that modifications may be made in form and detail without departing from the spirit and scope of the invention. Any use by reference to the above documents is limited so as not to refer to subject matter contrary to the express disclosure herein. As suggested by the description, unless otherwise specifically indicated, to the extent that a particular structure, composition and / or process comprising components, elements, raw materials or other classifications is described herein, it is understood that the disclosure herein covers particular embodiments, embodiments comprising particular components, elements, raw materials, other classifications or combinations thereof, and embodiments that are essentially derived from such particular components, raw materials or other classifications or combinations thereof, which may include additional features that do not alter the fundamental nature of the subject matter.
Claims
1. a precursor blend solution comprising an aqueous solvent, a first precursor having a hydrophilic core and succinimidyl ester functional groups, and a second precursor having a plurality of amine functional groups, the precursor blend solution having an acidic pH; and an accelerator solution comprising a buffer solution having a pH greater than 8.2, the accelerator solution comprising sufficient buffering capacity to raise the pH of a mixture of the precursor blend solution and the accelerator solution to a pH greater than 8; 1. A medical hydrogel system comprising:
2. 10. The medical hydrogel system of claim 1, wherein the hydrophilic core comprises a polyether, a copolymer of a polyether, a poloxamer, a polyvinyl alcohol, a poly(vinylpyrrolidinone), a poly(amino acid), a polysaccharide, or a protein.
3. The medical hydrogel system of claim 1 , wherein the hydrophilic core comprises polyethylene glycol.
4. The medical hydrogel system of claim 1 , wherein the hydrophilic core comprises a poloxamer or hyaluronic acid.
5. 10. The medical hydrogel system of claim 1, wherein the first precursor comprises a multi-arm polyethylene glycol.
6. The medical hydrogel system according to claim 5, wherein the multi-arm polyethylene glycol has 4 to 8 arms.
7. 2. The medical hydrogel system of claim 1, wherein the molecular weight of said first precursor is from about 5 kDa to about 40 kDa.
8. 2. The medical hydrogel system of claim 1, wherein the succinimidyl ester functional group comprises N-hydroxysuccinimidyl succinate (SS), N-hydroxysulfosuccinimidyl succinate, N-hydroxysulfosuccinimidyl glutarate, succinimidyl glutarate (SG), or a mixture thereof.
9. 2. The medical hydrogel system of claim 1, wherein the first precursor comprises polyethylene glycol having a molecular weight of about 10K to about 25K and 4 to 8 arms, wherein the arms terminate in N-hydroxysuccinimidyl succinate (SS) or succinimidyl glutarate (SG) functional groups.
10. 10. The medical hydrogel system of claim 1, wherein the second precursor comprises lysine, dilysine, trilysine, tetralysine, pentalysine, polyethyleneimine, or amine-terminated polyethylene glycol.
11. 2. The medical hydrogel system of claim 1, wherein said precursor blend solution comprises a molar ratio of said succinimidyl ester functional groups to said amine functional groups of from about 2 to about 0.
5.
12. 2. The medical hydrogel system of claim 1, wherein the precursor blend solution comprises a molar ratio of the succinimidyl ester functional groups to the amine functional groups of about 1.
13. 12. The medical hydrogel system of claim 11, wherein the weight solids percentage of the mixture is at least about 6%.
14. 10. The medical hydrogel system of claim 1, wherein the weight solids percentage of the mixture is from about 7.5% to about 15%.
15. 10. The medical hydrogel system of claim 1, wherein the acidic pH is in the range of about 4 to about 5.5 and is buffered.
16. The medical hydrogel system of claim 1, wherein the solvent comprises an acidic biological buffer having a concentration of about 0.002 M to about 0.15 M.
17. 17. The medical hydrogel system of claim 16, wherein the acidic biological buffer comprises a monobasic sodium phosphate buffer having a pH of about 4 to about 5.
5.
18. 10. The medical hydrogel system of claim 1, wherein the pH of the enhancer solution is in the range of about 8.5 to 10.
0.
19. 2. The medical hydrogel system of claim 1, wherein the buffer concentration of the enhancer solution is about 0.05M to 1.0M.
20. 20. The medical hydrogel system of claim 18, wherein the enhancer solution comprises one or more biological buffers including borate, phosphate, citrate, bicarbonate, CHES, TAPS, bicine, tris, or tricine.
21. 10. The medical hydrogel system of claim 1, further comprising an ultrasound contrast agent.
22. 10. The medical hydrogel system of claim 1, further comprising a radiopaque agent.
23. 2. The medical hydrogel system of claim 1, wherein the aqueous solvent comprises an acidic biological buffer, the first precursor comprises polyethylene glycol having a molecular weight of about 10 kDa to about 50 kDa, 4-8 arms, and succinimidyl glutarate (SG) and / or N-hydroxysuccinimidyl succinate (SS) functional groups, and the second precursor comprises trilysine acetate or polyethylene glycol having a molecular weight of about 10 kDa to about 25 kDa, 6-8 arms, and primary amine functional groups, wherein the precursor blend solution has a pH of about 3.8 to about 4.2, and a molar ratio of the SG functional groups to the primary amine functional groups of about 1, and the accelerator solution comprises a biological buffer and has a pH of about 9.6 to about 10.1, wherein the weight solids percentage of the mixture is about 3.5% to about 15%, and the mixture further comprises a visualization agent.
24. 24. The medical hydrogel system of claim 23, wherein the visualization agent comprises solid particles comprising barium sulfate, titanium, bismuth chloride, or a combination thereof.
25. 2. The medical hydrogel system of claim 1, wherein the aqueous solvent comprises an acidic biological buffer, the first precursor comprises a polyethylene glycol having a molecular weight of about 30 kDa to about 50 kDa, 4-6 arms and succinimidyl glutarate (SG) functional groups, and the second precursor comprises a polyethylene glycol having a molecular weight of about 10 kDa to about 25 kDa, 6-8 arms and primary amine functional groups, wherein the precursor blend solution has a pH of about 3.8 to about 4.2 and a molar ratio of the SG functional groups to the primary amine functional groups of about 1, and the accelerator solution comprises a biological buffer and has a pH of about 9.6 to about 10.
1.
26. 2. The medical hydrogel system of claim 1, wherein the aqueous solvent comprises an acidic biological buffer, the first precursor comprises polyethylene glycol with a molecular weight of about 10K to about 25K, 6-8 arms and succinimidyl glutarate (SG) functional groups, and the second precursor comprises trilysine acetate, wherein the precursor blend solution has a pH of about 3.8 to about 4.2 and a molar ratio of the SG functional groups to the amine functional groups of about 1, and the accelerator solution comprises a biological buffer and has a pH of about 9.6 to about 10.
1.
27. 2. The medical hydrogel system of claim 1, wherein the aqueous solvent comprises an acidic biological buffer, the first precursor comprises polyethylene glycol with a molecular weight of about 15K to about 30K, 4-6 arms and succinimidyl glutarate (SG) functional groups, and the second precursor comprises trilysine acetate, wherein the precursor blend solution has a pH of about 3.8 to about 4.2 and a molar ratio of the SG functional groups to the amine functional groups of about 1, and the accelerator solution comprises a biological buffer and has a pH of about 9.6 to about 10.
1.
28. 2. The medical hydrogel system of claim 1, wherein the aqueous solvent comprises an acidic biological buffer, the first precursor comprises polyethylene glycol having a molecular weight of about 10K to about 25K, 6-8 arms and N-hydroxysuccinimidyl succinate (SS) functional groups, and the second precursor comprises trilysine acetate, wherein the precursor blend solution has a pH of about 3.8 to about 4.2 and a molar ratio of the SS functional groups to the amine functional groups of about 1, and the accelerator solution comprises a biological buffer and has a pH of about 9.6 to about 10.
1.
29. 1. A method for preventing the formation of adhesions in a body cavity, comprising: Combining the precursor blend solution of any one of claims 1 to 28 with an accelerator solution to form a blend solution; and directing the blended solution into a catheter to deliver the blended solution into a body cavity, the blended solution being covalently crosslinked to gel in about 30 seconds or less. A method comprising:
30. 1. A hydrogel delivery system suitable for intrauterine delivery comprising: A first solution; A second solution; and an applicator comprising: a catheter configured for transcervical placement in a uterus, the catheter including a cap element on the catheter to allow for stemming of hydrogel out of the cervix; a first reservoir for holding the first solution; a second reservoir for holding the second solution; and a mixer configured to receive the first solution and the second solution and vigorously mix the first solution and the second solution to form a blended precursor solution for delivery from the mixer to the catheter, the blended precursor solution having a solids content of 5 weight percent (wt%) to 12 wt%. Including, The blended precursor solution gels in about 30 seconds or less and after 12 hours forms a product hydrogel having an initial Young's modulus of greater than 1 kPa, and the product hydrogel persists in a uterine environment for 3-29 days.
31. 31. The hydrogel delivery system of claim 30, wherein the blended precursor solution gels in about 1 to about 5 seconds.
32. 31. The hydrogel delivery system of claim 30, wherein the initial Young's modulus is from about 20 kPa to about 150 kPa.
33. 31. The hydrogel delivery system of claim 30, wherein the Young's modulus of the product hydrogel after 14 days in a uterine environment is greater than about 10% of the initial Young's modulus.
34. 31. The hydrogel delivery system of claim 30, wherein the product hydrogel persists in a uterine environment for 3-14 days.
35. 31. The hydrogel delivery system of claim 30, wherein the product hydrogel swells by no more than 125% up to 24 hours after formation.
36. 31. The hydrogel delivery system of claim 30, wherein a radiopaque agent is covalently bonded to the product hydrogel.
37. 31. The hydrogel delivery system of claim 30, wherein the product hydrogel is visible under ultrasound.
38. 38. The hydrogel delivery system of any one of claims 30 to 37, wherein the first solution comprises a first precursor comprising a multi-arm polyethylene glycol.
39. 39. The hydrogel delivery system of claim 38, wherein the multi-armed polyethylene glycol has 4 to 8 arms.
40. 38. The hydrogel delivery system of any one of claims 30 to 37, wherein the first solution comprises a first precursor having a molecular weight of about 5 kDa to about 40 kDa.
41. 38. The hydrogel delivery system of any one of claims 30 to 37, wherein the first solution comprises a first precursor having succinimidyl ester functional groups comprising N-hydroxysuccinimidyl succinate (SS), N-hydroxysulfosuccinimidyl succinate, N-hydroxysulfosuccinimidyl glutarate, succinimidyl glutarate (SG), or a mixture thereof.
42. 38. The hydrogel delivery system of any one of claims 30 to 37, wherein the second solution comprises a second precursor comprising lysine, dilysine, trilysine, tetralysine, pentalysine, polyethyleneimine, or amine-terminated polyethylene glycol.
43. 38. The hydrogel delivery system of any one of claims 30 to 37, wherein the precursor blend solution comprises a molar ratio of the succinimidyl ester functional groups to the amine functional groups of from about 2 to about 0.
5.
44. 38. The hydrogel delivery system of any one of claims 30-37, wherein the precursor blend solution comprises a molar ratio of the succinimidyl ester functional groups to the amine functional groups of about 1.
45. 38. The hydrogel delivery system of any one of claims 30 to 37, wherein the precursor blend solution has a weight solids percentage of about 7.5% to about 15%.
46. 38. The hydrogel delivery system of any one of claims 30 to 37, wherein the acidic pH of the first solution is in the range of about 4 to about 5.5 and is buffered.
47. 38. The hydrogel delivery system of any one of claims 30 to 37, wherein the first solution comprises a solvent that includes an acidic biological buffer at a concentration of about 0.002M to about 0.15M.
48. 38. The hydrogel delivery system of any one of claims 30 to 37, wherein the pH of the second solution is in the range of about 8.5 to 10.
0.
49. 38. The hydrogel delivery system of any one of claims 30 to 37, wherein the buffer concentration of the second solution is from about 0.05M to about 1.0M.
50. 1. A method for delivering an intrauterine hydrogel comprising: combining a first solution and a second solution to form a blend solution, the first solution comprising an aqueous solvent, a first precursor having a hydrophilic core and succinimidyl ester functional groups, and a second precursor having a plurality of amine functional groups, and the second solution comprising a buffer solution having a pH greater than 8.2; and directing the blended solution into a transcervically positioned catheter to deliver the blended solution into the uterus, the blended solution covalently crosslinking to gel in about 30 seconds or less, the catheter having a cap element that can be used to prevent the blended solution from flowing out and to provide pressure to the gelling hydrogel to create an expansion filling. A method comprising:
51. 51. The method of claim 50, wherein the uterus contains residual fluid, and the volume of the residual fluid is less than or equal to the volume of the blended solution.
52. 52. The method of claim 51, further comprising removing residual fluid with the positioned catheter prior to said directing.
53. 52. The method of claim 51, wherein residual fluid drains away and the blended solution forms a hydrogel in situ to effectively fill the uterine cavity.
54. 54. The method of claim 53, wherein the hydrogel persists in the uterus for 3 to 29 days.
55. 51. The method of any one of claims 50 to 50, wherein a first syringe contains the first solution and a second syringe contains the second solution, and the blended solution is covalently crosslinked to gel in about 1 second to about 10 seconds.
56. 56. The method of claim 55, wherein a volume of the first solution and a volume of the second solution are equal, and the first syringe and the second syringe are connected by a plunger cap, and directing the blended solution into the positioned catheter comprises depressing the plunger cap to deploy equal volumes of the first solution and the second solution.
57. the catheter includes an outflow limiter comprising a tubular member, and the cap element is fixedly attached to the tubular member at or near a distal end of the tubular member, an inner diameter of the outflow limiter is greater than an outer diameter of the catheter allowing the outflow limiter to slide over the catheter, and the outflow limiter is positioned to adjust a distal catheter length, the distal catheter length comprising a length from a distal end of the catheter to a distal end of the cap element; 57. The method of any one of claims 50 to 56, further comprising inserting the catheter into the uterus until the cap element is positioned against the cervix prior to said orienting.
58. 58. The method of claim 57, further comprising measuring a fundal depth with a uterine probe and adjusting the distal catheter length using the fundal depth measurement.
59. 58. The method of claim 57, further comprising removing the catheter after a selected period of time, leaving the outflow limiter in place to prevent fluid from exiting the neck.
60. 60. The method of claim 59, further comprising removing the outflow limiter after a selected period of time while leaving an in situ forming hydrogel in the uterine cavity.
61. 58. The method of any one of claims 57, further comprising monitoring the delivery of the blended solution into the uterus by ultrasound.
62. 54. The method of claim 53, wherein the formed hydrogel acts as a tamponade to prevent further fluid outflow.
63. 54. The method of claim 53, wherein the hydrogel comprises gas microbubbles, microparticles containing a therapeutic agent, hydrophobic microdomains, hydrogel particles, suspended inorganic particles, and / or microparticles of a therapeutic agent.
64. 54. The method of claim 53, wherein the hydrogel comprises iodine, TIB, 2,3,5-triiodobenzoic acid, 3,4,5-triiodophenol, erythrosine, rose bengal, 3,5-bis(acetylamino)-2,4,6-triiodobenzoic acid, and 3,5-diacetamido-2,4,6-triiodobenzoic acid, barium sulfate, titanium dioxide, bismuth chloride, or combinations thereof.
65. 51. The method of claim 50, wherein the first solution and the second solution form a medical hydrogel system according to any one of claims 1 to 28.
